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  Summary 
 I 
Summary 
 The genotypic and phenotypic characteristics of HIV-1 CRF02_AG strains from infected 
patients in Burkina Faso were determined in order to understand about resistance development and 
susceptibility to antiretroviral drugs of HIV-1 non-subtype B. Drug resistance studies among 
Nevirapine (NVP) naïve and exposed women from Nouna, and HAART-exposed HIV patients 
attending the University Hospital in Ouagadougou, Burkina Faso were performed. The diversity and 
evolution of HIV-1 reverse transcriptase (RT) quasispecies in paired plasma, breast milk whey and/or 
breast milk cells from seventeen HIV-infected NVP-naïve and exposed women were determined by 
direct sequencing and clonal analysis. NVP resistance mutations were detected in 8% of infected 
mothers by direct sequencing. By using clonal analysis, the detection rate increased to 46% which 
indicates the high sensitivity of clonal analysis in detecting low proportion of drug resistance variants. 
To analyze compartmentalization of virus population in different anatomic compartments, 
phylogenetic analysis comparing virus populations of plasma, breast milk and/or breast milk cells from 
individual patients at both single and multiple time points was performed and the circulation of both 
compartmentalized (50%) and non-compartmentalized (45.5%) variants were found. These results 
suggest that in some individuals, viruses in breast milk whey may be evolving separately from plasma 
viruses. In most cases, breast milk whey variants were completely different from those of breast milk 
cells suggesting that free HIV virions in breast milk do not originate from infected breast milk cells. 
Different resistance mutation patterns were observed between viruses in plasma, breast milk and breast 
milk cells which suggest that transmission of HIV-1 from mother-to-child via breastfeeding may 
involve variants harbouring resistance mutations which cannot be predicted from variants present in 
plasma.  
 To determine possible influences of genetic background on drug susceptibility of virus, a new 
CRF02_AG proviral plasmid (pBD6TB9RI) and the derivative CRF02_AG/subtype B chimera 
containing PR-RT fragment of pNL4-3 were generated. By testing drug susceptibility against 5 
protease inhibitors (PIs), 6 nucleoside reverse transcriptase inhibitors (NRTIs), and 3 non-nucleoside 
reverse transcriptase inhibitors (NNRTIs), the CRF02_AG virus showed similar phenotypic results 
like the CRF02_AG/subtype B chimera. To further evaluate the CRF02_AG plasmid backbone, PR-
RT amplified fragments derived from HAART-experienced HIV patients were cloned into the 
pBD6TB9RI plasmid and transfection derived viruses were tested against the panel of antiretroviral 
drugs. The phenotypic results for both NRTIs and NNRTIs strongly correlated with the predicted 
genotypic resistance patterns. However, there were minor discordances with some PIs. This suggests 
that the novel recombinant viral assay should be useful in assessing the drug susceptibility of 
CRF02_AG and other non-B strains which are widely distributed in West and Central Africa. 
 
 
 
  Zusammenfassung 
 II 
Zusammenfassung 
 Die genotypische und phänotypische Eigenschaften von HIV-1 CRF02_AG Subtyp von 
infizierten Patienten aus Burkina Faso wurden bestimmen um die Entwicklung der Resistenz und die 
Suszeptibilität für antivirale Medikamenten dieses HIV-1 Subtypes zu verstehen.  In dieser Arbeit 
wurde die Resistenz von HIV gegen antivirale Medikamenten in Nevirapin (NVP)-naiven bzw. –
therapierten Patientinnen aus Nouna und HIV-Patienten unter hochaktiver antiretroviraler Therapie 
(HAART) am Universitätsklinikum in Ouagadougou, Burkina Faso untersucht. Die Diversität und die 
Evolution der HIV-1 Reverse Transkriptase (RT) Quasispezies im Blutplasma Muttermilch und/oder 
Muttermilchzellen von siebzehn HIV-infizierten, NVP-naiven bzw. -therapierten Patientinnen wurde 
durch direkte Sequenzierung und Klonalanalyse ermittelt. Die Ergebnisse zeigen, dass die klonale 
Analyse eine höhere Sensititvität bei dem Nachweis von Resistenzvarianten aufweist, die in der 
Viruspopulation nur in einem kleinen Anteil vorliegen. Während die direkte Sequnzierung nur bei 8% 
der HIV-infizierten Mütter NVP-Resistenzmutationen nachwies, wurden durch  Klonalanalyse bei 
46% dieser Frauen Mutationen detektiert.  
 Die Kompartimentierung von Viruspopulationen in Blutplasma gegenüber Muttermilch 
und/oder Zellen aus Muttermilch wurde mittels phylogenetischer Methoden analysiert. In 50% der 
Fälle zeigte sich eine Kompartimentalisierung der Viruspopulationen. Dies weist darauf hin, dass 
zumindest in einem Teil der Patientinnen eine unabhängige Entwicklung der Viren in Muttermilch 
stattfindet. Da sich die Viren in Muttermilch in den meisten Fällen von den Viren in Muttermilchzellen 
unterschieden, kann man annehmen, dass die freie HIV-Virionen in Muttermilch nicht von der 
Mehrzahl der infizierten Muttermilchzellen stammten. Aufgrund des Unterschieds von HIV-Varianten 
in Blutplasma, Muttermilch und Muttermilchzellen ist anzunehmen, dass Resistenzmutationen 
enthaltende Viren außerhalb von Blutplasma bei der Mutter-Kind Übertragung durch das Stillen eine 
wichtige Rolle spielen. Dies muss berücksichtigt werden, weil die meisten HIV-infizierten Mütter in 
Afrika ihre Kinder noch stillen.            
 Um mögliche Einflüsse des viralen Genotyps auf die Suszeptibilität von HIV gegnüber 
antiretroviralen Medikamenten zu untersuchen, wurde ein prototypisches provirales Plasmid des in 
Westafrika verbreiteten AG rekombinanen Subtyps (pBD6TB9RI) hergestellt, und die Sensitivität 
dieses Virus gegenüber 5 Protease-Inhibitoren (PI), 6 nukleosidischen Reverse-Transkriptase-
Inhibitoren (NRTI) und 3 nichtnukleosidischen Reverse-Transkriptase-Inhibitoren (NNRTI) bestimmt. 
Ein Austausch der PR-RT kodierenden Region mit entsprechenden Sequenzen aus dem Subtyp B 
Isolat NL4-3 bewirkte keine Veränderung des Sensitivitätsprofils.   Anschließend wurde die PR-RT 
Region aus Viren aus dem Plasma von Patienten unter HAART in pBD6TB9RI überführt und die 
Suszeptibilität der rekombinanten Viren gegen die verschiedenen Inhibitoren getestet. Überwiegend 
ergab sich eine Übereinstimmung mit der genotypischen Vorhersage. Im Fall der PI ergaben sich zum 
Teil jedoch Abweichungen zwischen den Ergebnissen der genotypischen und der phnotypischen 
Bestimmung. Dies zeigt den Nutzen des hier etablierten phänotypischen Resistenztests für Viren des 
AG rekombinanten Subtyps. 
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1 Introduction 
 
1.1 Human Immunodeficiency Virus (HIV)  
 The human immunodeficiency virus (HIV) causes a chronic infectious disease 
known as the acquired immunodeficiency syndrome (AIDS), which progressively 
damages the host’s immune system. HIV belongs to the lentivirus subfamily of 
retroviruses (family Retroviridae). HIV genome is encoded as a positive sense RNA 
which is transcribed into double stranded DNA by the reverse transcriptase enzyme, the 
most noticeable feature of retroviruses (Vogt, 1997). 
 Since HIV was discovered in 1983, it has rapidly emerged as one of the most 
devastating infectious pathogens of this century (Gallo et al., 1983). By the end of 2007, 
an estimated 30 million people worldwide were living with HIV of whom 2.1 million 
were children. Approximately 2.5 million new infections occurred in 2007 with 1.7 
million (68%) of these in sub-Saharan Africa (UNAIDS/WHO, 2008). 
  
 1.1.1 HIV-1 structure and genomic organization 
 The HIV-1 virion has a spherical structure with an approximate size of 145 nm in 
diameter (Briggs et al., 2003). The virion contains two copies of single stranded HIV-1 
genomic RNA encoding the structural protein (Gag), enzymatic protein (Pol), 
glycoprotein (Env) and accessory proteins (e.g. Vif, Vpr, Vpu, Nef, Rev, Tat) that 
regulate gene expression and modulate pathology (Fig. 1).  
 The gag gene synthesizes the structural polyprotein precursor Gag (Pr55Gag) 
consisting of the matrix (MA, p17), capsid (CA, p24), nucleocapsid (NC, p7) and p6 
domains as well as two spacer peptides (SP1 and SP2). The Pol proteins consist of the 
viral enzymes protease (p11), reverse transcriptase/Rnase H (p51/p66) and integrase 
(p32) which are generated by subsequently cleavage of the Gag-Pol polyprotein precursor 
(Pr160). The Env protein is expressed as a precursor glycoprotein gp160 that is 
subsequently cleaved by the cellular protease furin into the surface protein gp120 (SU) 
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and the transmembrane protein gp41 (TM). The long terminal repeats (LTRs) flank the 
coding region and are necessary for reverse transcription and integration (Fig. 1). 
 
A.
B.    
                               
Fig. 1 Genomic organization of HIV-1. (A) The open reading frames of the viral proteins are depicted. 
The virus structural genes are shaded and the accessory genes and the LTR are shown as open boxes. LTR, 
Long terminal repeat; MA, matrix; CA, capsid; NC, nucleocapsid; PR, protease; RT, reverse transcriptase; 
IN, integrase; TM, transmembrane glycoprotein; SU, surface glycoprotein. (B) Typical representation of a 
mature HIV particle: spherical, approximate 100 nm in diameter and consisting of a lipid bilayer membrane 
surrounding a conical nucleocapsid. Adapted from Knipe et al.,2001. 
 
 
 1.1.2 Replication cycle 
 HIV-1 infection begins with the interaction of gp120 with the cellular CD4 
receptor on the surface of the target cells (Dalgleish et al., 1984). Subsequently, an 
interaction between gp120 and the chemokine receptor CCR5 or CXCR4 occurs leading 
to a conformational change exposing gp41, which induces fusion of the virus and cell 
membrane (Stein et al., 1987). After fusion, HIV releases the core into the cytoplasm of 
the target cell. In the cytosol, viral reverse transcriptase (RT) synthesizes a double 
stranded DNA from single stranded viral RNA. Inside the nucleus, the viral DNA is 
integrated into the host genome by HIV-1 integrase (IN) enzyme, resulting in the so 
called provirus which can remain latent or lead to active synthesis of the viral progeny 
(Bushman et al., 1990). Viral transcription is achieved by cellular RNA polymerase II 
Tat 
Rev 
 5’LTR 
MA CA NC p6 
RT PR IN Vpr SU TM 3’LTR GAG 
POL ENV Vif Vpu Nef 
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which transcribes viral DNA into mRNA. Subsequently, viral mRNAs are exported to the 
cytoplasm for translation as polyproteins and associate with other viral components to 
form the immature, non-infectious particles. The immature virions are release from host 
cell membrane where they acquire viral envelope proteins. Finally, the viral polyprotein 
precursors within the immature particles are proteolytically processed by the viral 
protease (PR) enzyme leading to the development of mature infectious HIV virions. The 
free mature HIV-1 virions can further infect other cells and initiate their life cycle 
(Coffin, 1997) (Fig. 2). 
 
           
Fig. 2 HIV-1 replication cycle. This figure is adapted from De Clercq, 2002 and the replication cycle is 
described in the text. 
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 1.1.3 Classification of immunodeficiency viruses 
 HIV belongs to the primate lentivirus subfamily of retroviruses and can be divided 
into 2 groups; HIV-1, HIV-2. HIV-1 and HIV-2 are highly divergent with their envelope 
protein sequences differing by as much as 60%, reflecting their distinct origin (Sharp, 
2002). 
 Presently, HIV-1 is subdivided into 3 groups: Major (M), Outlier (O) and non-
M/non-O (N). However, very recently, a new strain of HIV-1 similar to SIVs gorilla was 
isolated from a Cameroonian living in France and was tentatively called HIV-1 group P 
(Plantier et al. 2009). Group M is responsible for the majority of infections worldwide 
and can be divided into 9 subtypes (A-D, F-H, J and K), 5 sub-subtypes (A1-A3 and F1-
F2) and 43 circulating recombinant forms (CRFs) (Robertson et al., 2000; Tebit et al., 
2007; Kuiken et al. 2009). Comparing the protein coding sequences between HIV-1 
subtypes a nucleotide diversity of up to 30% is observed in env, 20% in gag and 15% in 
pol (Gao et al., 1997).  
Group O viruses show high variability between isolates. Partial gag, pol and env 
sequences have been used to classify group O viruses into putative subtypes (Mas et al., 
1999; Roques et al., 2002). These studies indicate a high diversity of group O and do not 
show the same subtype formation like group M viruses (Fig. 3) (Quinones-Mateu et al., 
1998; Yamaguchi et al., 2003). The group N viruses form an independent clade related to 
group M, whereas sequences from the 3’ end cluster more closely with SIVcpzUS 
chimpanzee virus, suggesting a possible ancient recombination within humans or prior to 
cross-species transmission (Fig. 3) (Gao et al., 1999; Corbet et al., 2000). 
 HIV-2 subtypes are mainly restricted to West Africa and can be categorized as 
epidemic subtypes (A-B) and non-epidemic subtypes (C-G) (Lemey et al., 2003). 
Individuals infected with HIV-2 develop AIDS as well, but with a longer incubation 
period and lower morbidity (Gao et al., 1994).  
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Fig. 3 Phylogenetic tree representing the genetic diversity in HIV-1 group M, N, O and SIVcpz. 
HIV-2 was use as the out group. Subtype and CRFs are represented in black and different shades of gray. 
Within the HIV-1 group M the term "x-like" is used to denote clusters which are similar to the different 
group M subtypes. Adapted from Tebit et al., 2007. 
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1.2 Circulating recombinant forms (CRFs) 
 HIV recombination occurs when a single cell is infected by two different viruses 
to generate a heterozygous or heterodiploid virion. Due to the switching of the reverse 
transcriptase between RNA genomes during minus (-) strand DNA synthesis (Preston and 
Dougherty, 1996; Temin, 1993; Wain-Hobson, 1992), de novo infection by this 
heterodiploid virus yields a recombinant retroviral DNA sequence. HIV-1 can recombine 
not only within subtypes (intra-subtype recombination), but also between subtypes (inter-
subtype recombination) and groups (inter-group recombination) (Morris et al., 1999; 
Peeters, 2000; Takehisa et al., 1999).   
 In general, circulating recombinant forms (CRFs) are recombinants which are 
comprised of two different subtypes (Table 1). However, some CRFs are composed of 
more than two different subtypes, so called complex CRF (CRFcpx) (Table 1). These 
recombinants may occur due to recombination events between CRFs and other pure 
subtypes (Table 1). CRFs are responsible for about 10-20% of all new infections 
(Robertson et al., 2000; Peeters and Sharp, 2000). The most dominant forms in the 
epidemic are the CRF01_AE, CRF02_AG, CRF07, 08_BC and CRF12_BF viruses found 
in Asia, West Africa, China and South America, respectively (Table 1). 
 
 
Table 1. Characteristics and geographical distribution of circulating recombinant forms 
(CRFs) (adapted from Kuiken et al., 2009; Tebit et al., 2007). 
Name Reference strain Subtypes Distribution Fitness 
Identified 
sequencesa 
CRF01_AE CM240  A, E Thailand, central Africa group M-like 6332 
CRF02_AG IbNG  A, G West and central Africa AG>A=G 3769 
CRF03_AB Kal153  A, B Eastern Europe unknown 149 
CRF04_cpx 94CY032  A, G, H, K, U Cyprus, Greece unknown 22 
CRF05_DF VI1310  D, F Belgium unknown 29 
CRF06_cpx BFP90  A, G, J, K West Africa unknown 845 
CRF07_BC CN54  B', C China, Taiwan unknown 136 
CRF08_BC GX-6F  B', C China unknown 187 
CRF09_cpx 96GH2911  CRF02, A, U West and central Africa unknown 39 
CRF10_CD TZBF061  C, D East Africa unknown 202 
CRF11_cpx GR17  A, CRF01, G, J Central Africa unknown 529 
CRF12_BF ARMA159  B, F South America F>B=BF b 348 
CRF13_cpx 96CM-1849  A, CRF01, G, J, U Central Africa unknown 78 
CRF14_BG X397  B, G Europe, Asia unknown 90 
CRF15_01B 99TH.MU2079  CRF01, B Thailand unknown 18 
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Table 1. Characteristics and geographical distribution of circulating recombinant forms 
(CRFs) (adapted from Kuiken et al., 2009; Tebit et al., 2007) (continued) 
 
a = global estimate based on information from the HIV database and published data; b = preliminary results, 
analysis in progress; c = all BF-like viruses combined, NA= data not available; pending = sequences is still 
to be determined 
 
 
1.3 Routes of HIV-1 transmission 
 HIV-1 can be transmitted by both homosexual and heterosexual contact with 
infected partners (Clumeck et al., 1985; Kingsley et al., 1989). HIV-1 can be isolated 
from both semen and female genital secretions (Ho et al., 1984; Wofsy et al., 1986). 
Name Reference strain Subtypes Distribution Fitness 
Identified 
sequencesa 
CRF16_A2D KISII5009  A2, D 
Kenya, Korea, 
Argentina unknown 
6 
CRF17_BF ARMA038 B, F South America F>B=BF b 7 
CRF18_cpx CU76 A1, F, G, H, K, U Cuba, central Africa unknown 36 
CRF19_cpx CU7 A1, D, G Cuba unknown 10 
CRF20_BG CB228 B, G Cuba unknown 5 
CRF21_A2D 99KE_KER2003 A2, D Kenya unknown 2 
CRF22_01A1 CM53122 CRF01, A1 Cameroon unknown 3 
CRF23_BG CB118 B, G Cuba unknown 2 
CRF24_BG CB378 B, G Cuba unknown 3 
CRF25_cpx 02CM_1918LE A, G, U Cameroon unknown 2 
CRF26_AU 02CD_MBTB047 A, U Pending unknown NA 
CRF27_cpx 97CDKTB49 A, E, G, H, J, K D.R.C unknown 9 
CRF28_BF BREPM12609 B, F South America F>B=BF b 2 
CRF29_BF BREPM16704 B, F South America F>B=BF b 3 
CRF30_0206 00NE36 CRF02,CRF06 Niger unknown 1 
CRF31_BC 04BR142 B, C Brazil unknown 17 
CRF32_06A1 EE0369 CRF06, A1 
Eastern Europe 
(Estonia) 
unknown 
23 
CRF33_01B 05MYKL007_1 CRF01, B Asia (Malaysia) unknown 4 
CRF34_01B OUR2478P CRF01, B Thailand unknown 3 
CRF35_AD AF095 A, D Afghanistan unknown 4 
CRF36_cpx 
 
NYU830 
 
CRF01, CRF02, 
A, D 
Cameroon 
 
unknown 2 
CRF37_cpx 
 
NYU926 
 
CRF01, CRF02, A, 
G, U 
Cameroon 
 
unknown 2 
CRF38_BF1 UY05_4752 Pending Uruguay unknown 3 
CRF39_BF 03BRRJ103 B, F Brazil unknown 3 
CRF40_BF 04BRRJ115 B, F Brazil unknown 4 
CRF41_CD CO6650V1 C, D Pending unknown 3 
CRF42_BF luBF_13_05 B, F1 Luxembourg unknown 21 
CRF43_02G J11223 CRF02, G Saudi Arabia unknown 4 
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Transmission also occurs by transfusion of whole blood, cellular blood components, 
plasma and clotting from HIV-1 infected subjects to the recipients (Curran et al., 1984; 
Ward et al., 1987). HIV is transmitted among injecting drug users (IVDU) via 
contaminated needles. Risk factors of IVDU also include frequency of needle sharing, 
injections and prevalence of HIV infection in the area (Des Jarlais et al., 1989; 
Schwenbaum et al., 1989). 
      Transmission from an HIV infected mother to the newborn has been shown to occur 
across the placenta (Lapointe et al., 1985), at the time of delivery by exposure to 
maternal secretion or post-delivery via breast feeding (Van de Perre et al., 1992; Ziegler 
et al., 1985). Breast feeding has been identified as an important route for vertical 
transmission of HIV-1 (Dunn et al., 1992; John et al., 2001), particularly in sub-Saharan 
Africa where antiviral therapy and infant formula are not widely available (Nduati et al., 
2000). Transmission of HIV from mother-to-child through breast milk (BM) is 
associated with several factors such as maternal viral load, cell-free and cell-associated 
HIV in breast milk, low maternal CD4 cell count and mastitis (Coovadia et al., 2007; 
Rousseau et al., 2004). Transmission can take place at any point during lactation and the 
cumulative probability of acquisition of infection increases with duration of breast 
feeding (Miotti et al., 1999). 
 
 
1.4 Antiretroviral therapy and drug resistance mutations 
 There are currently 5 classes of drugs approved by the United States Food and 
Drug Administration (US FDA) for HIV-1 treatment (Table 2). Most of the antiretroviral 
drugs target viral enzymes such as the protease inhibitors (PIs), reverse transcriptase 
inhibitors (RTIs) consisting of nucleoside/nucleotide RT inhibitors (NRTIs) and non-
nucleoside RT inhibitors (NNRTIs), and integrase inhibitor (INI). Two entry-inhibitors, 
enfuvirtide and maraviroc are also available for HIV-1 therapy. 
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 Table 2. Antiretroviral drugs for HIV-1 treatment  
 
Class Drugs 
NRTIs Abacavir (ABC) 
 Didanosine (ddI) 
 Emtricitabine (FTC) 
 Lamivudine (3TC) 
 Stavudine (d4T) 
 Tenofovir (TDF) 
 Zidovudine (ZDV,AZT) 
NNRTIs Efavirenz (EFV) 
 Etravirinea (ETR) 
 Nevirapine (NVP) 
PIs Atazanavirb (ATV) 
 Darunavirb (DRV) 
 Fosamprenavirb (FPV) 
 Indinavirb (IDV) 
 Lopinavirb (LPV) 
 Nelfinavir (NFV) 
 Saquinavirb (SQV) 
 Tipranavirb (TPV) 
INI Raltegravir (RAL) 
Entry inhibitors Enfuvirtide (T-20) 
Maraviroc (MVC) 
 
a = ETR shows activity against HIV strains that are resistant to previously approved NNRTIs. 
b = PIs are currently used in combination with Ritronavir (RTV) which acts as a pharmacologic booster. 
 
 
HIV-1 mutations occur due to the rapid turnover and high error rate of reverse 
transcriptase which lacks 3’- 5’ exonuclease proof reading activity (Preston et al., 1988). 
These mutations facilitate HIV-1 to escape from the immune system (Ho et al., 1995; 
Piatak et al., 1993) and also facilitate the escape from antiretroviral drug pressure 
resulting in the emergence of drug resistant viruses which account for a large portion of 
treatment failures (Coffin, 1996).  
In general, primary or major mutations decrease drug susceptibility by themselves, 
whereas secondary or minor mutations reduce drug susceptibility in combination with 
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primary mutations or improve the replicative fitness of virus isolates with primary 
mutations. 
 
 1.4.1 Protease inhibitors (PIs)  
 PIs bind to the active site of the viral protease enzyme and prevent the processing 
of viral proteins into functional forms. In this way, the new virions are unable to mature 
or become infectious. Mutations in the protease substrate cleft cause resistance by 
reducing the binding affinity between inhibitor and protease enzyme. Mutations 
elsewhere in the enzyme either cause resistance by altering enzyme catalysis, dimer 
stability, re-shaping the active site or compensate for the decreased kinetics of enzyme 
(Barbour et al., 2002; Erickson et al., 1999; Muzammil et al., 2003). 
       
Fig. 4 Mechanism of action of protease inhibitors. Protease inhibitors (indicated by dash gray arrow) 
bind to protease enzyme (indicated by solid black arrow) and prevent the polyprotein clevage (indicated by 
solid gray arrow). Adaped from Richman, 2001.  
 
 
 1.4.2 Nucleoside/nucleotide reverse transcriptase inhibitors 
 (NRTIs) 
 NRTIs have a similar molecular structure to the natural building blocks, dNTP. 
Both nucleoside and nucleotide analogs are prodrugs that must be phosphorylated by host 
cellular enzymes to become the active form. Phosphorylated NRTIs compete with natural 
dNTP for incorporation into a newly synthesized DNA strand, therefore they terminate 
the ongoing viral DNA synthesis (Richman, 2001; Shafer, 2002) (Fig. 5A). There are two 
biochemical mechanisms of NRTI drug resistance. The first mechanism is mediated by 
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mutations that allow the reverse transcriptase enzyme to distinguish between NRTIs and 
dNTPs during polymerization, thereby preventing the incorporation of NRTI to the DNA 
chain (Huang et al., 1998; Sarafianos et al., 1999). The second mechanism is mediated by 
mutations that promote the hydrolytic removal of the NRTI and permit DNA elongation 
(Arion et al., 2000; Mayer et al., 2003). 
 
 1.4.3 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
 NNRTIs are noncompetitive inhibitors which interact with an allosteric non-
substrate binding site of HIV-1 reverse transcriptase (De Clercq, 2002; Hsiou et al., 
2001). This interaction affects the activity of reverse transcriptase by restricted enzyme 
mobility and function (Richman, 2001) (Fig. 5B). NNRTIs do not require metabolic 
activation like NRTIs resulting as a high potency drug. However, NNRTI resistance 
usually emerges rapidly. A single mutation in the NNRTIs binding pocket can result in 
high-level resistance that can also confer cross-resistance to other drugs in the NNRTI-
group (Havlir et al., 1996; Jackson et al., 2000). 
 
                 
 
Fig. 5 Mechanism of action of reverse transcriptase inhibitors. (A) NRTI is incorporated into viral 
DNA and terminates viral DNA synthesis. (B) NNRTI binds to RT enzyme and inhibits RT enzyme 
activity. Adapted from Richman, 2001. 
 
 
A. 
B. 
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1.4.4 Integrase inhibitor (INI) 
 The HIV-1 integrase enzyme is responsible for the integration of viral DNA into 
the host cell genome. Integrase possesses two major catalytic activities: an 
endonucleolytic cleavage at each 3'-OH extremity of the viral genome, named 3'-
processing and a strand transfer reaction leading to the insertion of the processed viral 
DNA into the target DNA by a one-step trans-esterification (Ellison et al., 1990; Miller et 
al., 1997). Raltegravir is the first approved integrase inhibitor for clinical use. This 
inhibitor binds to integrase- viral DNA complex and thereby selectively blocks the strand 
transfer step (Delelis et al., 2008). However, resistance mutations to raltegravir have been 
reported. These mutations affect function of intergrase by altered both 3’ processing and 
strand transfer activities (Malet et al., 2008). 
 
1.4.5 Entry inhibitors 
 The first FDA approved entry inhibitor, enfuvirtide (T-20) is a 36–amino acid 
peptide derived from the heptad repeat 2 (HR2) region of the gp41 transmembrane 
domain of HIV-1 subtype B. T-20 is predicted to bind to a highly conserved hydrophobic 
groove located on the trimeric coiled coils of HR1, thereby preventing the formation of 
the six-helix bundle and inhibiting membrane fusion (Fig. 6). The amino acid position 36-
43 (GIVQQQNN) of heptad repeat 1 (HR1) primarily determines T-20 responsiveness. 
Therefore, changes within the GIV motif are sufficient to cause drug resistance to T-20 
(Reeves et al., 2005).  
                   
Fig. 6 Mechanisms of action of fusion inhibitor. After gp120 binds to a CD4+ cell, the transmembrane 
(TM) domain undergoes a conformational change that includes unfolding which results in the 'spring-
loaded' formation of coiled-coil helices in preparation for viral entry. Enfuvirtide (T-20) binds to the TM 
domain and prevents fusion to the host cell and viral entry. Adapted from Pomerantz & Horn, 2003. 
HR-1 
HR-2 
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 The second entry inhibitor, maraviroc, is a co-receptor antagonist which blocks 
entry of CCR5 (R5) tropic viruses to target cells (De Clercq, 2007). Viruses that can use 
both CCR5 and CXCR4 (termed dual/mixed or D/M) or only CXCR4 (X4) do not 
respond to maraviroc treatment (Westby et al., 2006; Wilkin et al., 2007). A virologic 
failure with maraviroc therapy is frequently associated with outgrowth of X4 virus that 
preexisted as a minor population below the level of assay detection (Johnson et al., 2008). 
   
1.4.6 HIV-1 treatment strategies and drug resistance mutations 
Current treatment strategies for HIV-1 infected individuals include the use of 
combination antiretroviral drug therapy also termed highly active antiretroviral therapy or 
HAART. The use of antiviral drugs has been shown to suppress HIV-1 replication and 
lead to a significant decrease in disease progression with improved clinical status (Pilcher 
et al., 1999). However, these combination strategies do not completely eliminate viruses 
and the viruses may rebound when the antiviral treatment is interrupted (Steingrover et 
al., 2008). One limitation of complex therapeutic regimens is that they may induce 
emergence of more complex resistance patterns. Several studies performed in both 
developed and developing worlds have reported the presence of resistance mutations 
among treatment-naïve HIV patients, suggesting transmission of resistant viruses (Little 
et al., 2002; Oette et al., 2006). Approximately 30 million people worldwide are infected 
with HIV and 68% of these infected people are living in sub-Sahara Africa 
(UNAIDS/WHO, 2008). The availability of HAART for HIV-infected people in sub-
Sahara Africa has also rapidly increased (Koening et al., 2006). Several studies reported 
the emergence of drug resistance in individuals undergoing treatment in African countries 
(Kantor et al., 2002; Petrella et al., 2001; Richard et al, 2004). Due to the extensive use of 
single-dose nevirapine (SD-NVP) to prevent mother-to-child transmission (PMTCT) in 
sub-Sahara Africa, NVP- associated mutations have been found most commonly (Arrive 
et al., 2007). 
 
 
1.5 Effects of single dose nevirapine (SD-NVP) and viral 
compartmentalization 
 Single dose Nevirapine (SD-NVP) given to women during labor and to infants 
within 72 hours of birth has been shown to be an effective and low cost intervention for 
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the reduction of mother-to-child transmission (MTCT) in resource limited countries 
(Jackson et al., 2003). However, administering SD-NVP can lead to rapid selection of 
resistant variants. The most common mutations among them are the K103N and/or 
Y181C mutations in reverse transcriptase which confer cross-resistance to other approved 
antiviral drugs in the NNRTI group (Deeks 2001; Richman et al., 1994). The K103N 
mutation appears to have little effect on the replication capacity of HIV-1 allowing this 
variant to persist long after NVP therapy is stopped (Lecossier et al., 2005; Palmer et al., 
2006a). Several studies have demonstrated that the frequency of NVP-resistance 
mutations decreases over time, but they can persist for more than 1 year in plasma after 
the exposure to SD-NVP (Flys et al., 2005; Palmer et al., 2006b). NVP resistant variants 
have been also detected in the breast milk of some SD-NVP exposed women (Kassaye et 
al., 2007; Lee et al., 2005) and transmission of NVP-resistant variants via breast feeding 
has been reported (Eshleman et al., 2001).  
Viral compartmentalization occurs due to constraints on viral entry and 
replication, target cell differences and differing immune responses in distinct anatomical 
sites that result in the independent selection of subsets of the virus population for 
continuous replication (Henderson et al., 2004). Moreover, the emergence of drug 
resistant strains may vary in diverse anatomical compartments and this variation can be 
attributed to the different pharmacokinetic properties of a particular drug (Kepler and 
Perelson, 1998; Wong et al., 1997). Several compartments such as cerebrospinal fluid 
(Lafeuillade et al., 2002), genital tract secretions (Overbaugh et al., 1996) and lymphoid 
tissue (Omrani and Pillay, 2000) have been shown to be poorly accessible to different 
antiretroviral drugs. 
In recent years, different anatomical compartments have been analyzed for the 
evolution of HIV-1 as well as for the emergence of drug resistance variants. Different 
compositions of viruses have been recovered from plasma and peripheral blood 
mononuclear cells (PBMC) during HIV-1 infection (Livingstone et al., 1996). Several 
studies have reported compartmentalization of HIV-1 between PBMC and mucosal 
compartment (Poss et al., 1995), PBMC and renal epithelial cells (Marras et al., 2002), 
blood and different anatomical compartments such as lung (Singh et al., 1999), brain, 
spleen and lymph node (Wong et al., 1997) and genital tract (Diem et al., 2008; Kemal et 
al., 2003) as well as body fluid (Delwart et al., 1998; Ellerbrock et al., 2001; Overbaugh 
et al., 1996) within an individual. However, information on the viral population and NVP 
associated drug resistance mutations in breast milk is still unclear (Becquart et al., 2002, 
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2007; Henderson et al., 2004; Lee et al., 2005). Such knowledge is important especially in 
Africa where breastfeeding is still highly practiced even by HIV infected mothers. 
 
 
1.6 Drug resistance assays 
 As the detection of resistance becomes an integral part of patient management, 
resistance tests have been recommended to clinicians to select the optimal drug regimens 
after the first or multiple treatment failures (Hirsch et al., 2003). Moreover, because of the 
emergence of drug resistance variants, resistance tests are also recommended in primary 
HIV infection (Little et al., 2002). Evaluation of drug resistance can be monitored by 
either genotypic or phenotypic assays.  
 
 1.6.1 Genotypic assays  
Genotypic assays are mostly based on DNA sequencing which can be performed 
by different methods. The dideoxynucleotide (Sanger) sequencing or chain termination 
method is carried out by using dye labeled dideoxynucleotides (ddNTPs) which are 
incorporated into the PCR product and lead to termination of elongation. The lengths of 
sequencing products are determined by the fluorescence spectra of the dye-label on an 
automated sequencing machine (Schuurman et al., 1999) (Fig. 7A). The Sanger 
sequencing method is widely used to detect drug resistance mutations from patient-
derived PCR products, so called direct PCR sequencing. However, direct PCR sequencing 
is unable to detect low proportions of drug-resistance variants in the heterogeneous virus 
population existing in a patient’s plasma sample (Palmer et al. 2005).  
Pyrosequencing is a DNA sequencing technique that is based on the detection of 
released pyrophosphate (PPi) during DNA synthesis (Ronagi et al., 1998). The nucleotide 
composition of a growing DNA-strand is determined by an enzyme cascade system 
(O’Meara et al., 2001; Ronaghi, 2001) (Fig. 7B). The ultra-deep pyrosequencing could 
detect minority variant harbouring drug-resistance mutations in antiretroviral-experienced 
patients in whom mutations were no longer detectable by standard direct PCR sequencing 
(Le et al., 2009; Wang et al., 2007). 
The other approaches to analyze viral genotype are based on the hybridization 
technique such as line probe assay (LiPA) (Stuyver et al., 1997), oligonucleotide ligation 
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assays (OLAs) (Beck et al., 2002; Troyer et al., 2008), and the high density 
oligonucleotide arrays (GeneChip) (Kozal et al., 1996; Wilson et al., 2000). 
 In general, genotypic assays are convenient to perform and relatively rapid but 
provide indirect evidence of resistance. Furthermore, it is difficult to interpret the 
sequences with unusual amino acid substitutions (Paolucci et al., 2003) or complex 
mutation patterns (Ross et al., 2001). 
 
Real time monitoring
DNA:sequence:
B.A.
DNA:sequence:
 
 
Fig. 7 Schematic representation of the DNA sequencing techniques. (A) Chain termination method 
(Sanger sequencing). The DNA template is added to a mixture containing dNTPs, a primer, a DNA 
polymerase and a limited amount of four dideoxynucleotides (ddATP, ddGTP, ddCTP, ddTTP) labelled 
with different fluorescence dyes that emits different colors upon laser excitation (above). An 
electropherogram showing the nucleotide composition of a particular sequence as determined by 
fluorescence (below). (B) Pyrosequencing method. The reaction mixture consists of single stranded DNA 
with an annealed primer and four enzymes. The four different nucleotides are added stepwise and the 
cascade starts with a nucleic acid polymerization reaction in which pyrophospate (PPi) is released as a 
result of nucleotide incorporation by DNA polymerase. The released PPi is subsequently converted to ATP 
by ATP sulfurylase which provides the energy to luciferase to oxidize luciferin and generate detectable 
light. The exceeded nucleotides are continuously degraded by enzyme apyrase allowing addition of 
subsequent nucleotide. dXTP indicates one of the four nucleotides (above). The pyrogram showing the 
nucleotide sequence in a specific section of DNA (below). This figure is adapted from O’Meara et al., 2001; 
Ronaghi, 2001 and http://clinical-virology.org/ 
 
 
 
   Introduction 
 17 
1.6.2 Phenotypic assays  
These assays determine the in vitro ability of an HIV-1 isolate to replicate in the 
presence of antiviral drugs and thus provide a direct quantitative resistance measurement. 
Previously, phenotypic drug susceptibility was performed by culturing viruses derived 
from patients’ peripheral blood mononuclear cells (PBMCs) and measuring the effects of 
different concentrations of a drug on viral replication in cell culture which was both labor 
intensive and time consuming (Japour et al., 1993). The novel methods based on the 
development of recombinant viruses have developed and these assays have been termed 
Recombinant Viral Assays (Kellam and Larder, 1994). In general, recombinant viruses 
are generated by amplification of patient derived protease-reverse transcriptase (PR-RT) 
sequences which are then inserted into a PR-RT-deleted provirus backbone, generally 
derived from HIV subtype B strains either by homologous recombination (Hertogs et al., 
1998) or direct cloning (Petropoulos et al., 2000; Klimkait, 2002; Paolucci et al., 2004; 
Garcia-Perez et al., 2007). The recombinant viruses therefore retain the drug 
susceptibility of the PR and RT of the patient sample. 
 
 
1.7 Global HIV distribution 
 HIV-1 subtype C comprises about 52% of all HIV infections in the world (Ghys et 
al., 2003). The highest prevalence of HIV-1 is found in Southern Africa which also has 
the lowest HIV-1 diversity due to the dominance of subtype C (Tebit et al., 2007) (Fig. 8). 
In East Africa (Fig. 8), subtypes A, D and C are the predominant strains (Zhu et al., 
1998). West and Central Africa has been described as an “HIV diversity hotspot”, 
because it carries a mixture of nearly all HIV strains. However, CRF02_AG is 
responsible for the majority of the HIV-1 infection in this part of Africa (Montavon et al., 
2000; Tebit et al., 2002) (Fig. 8). 
 Asia and Eastern Europe (Fig. 8) are currently observing a dynamic HIV 
epidemic. Although subtype B was the first strain introduced into many Asian countries, 
it has not been spread widely in comparison to other subtypes. In China, subtype C and B 
as well as the CRF07_BC and CRF08_BC are highly prevalent. Subtype C is the most 
common subtype found in India (Shankarappa et al., 2001) and CRF01_AE in South-East 
Asia (Carr et al., 1996) (Fig. 8). 
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 In Eastern Europe, sub-subtype A1 is dominant, but subtype B and CRF03_AB 
also co-circulate (Liitsola et al., 1998). In North America, Western Europe and Australia, 
subtype B is the most prevalent form of HIV-1 (Fig. 8). However, there has been a rapid 
increase in non-B subtypes and CRFs in Western Europe (Hemelaar et al., 2004). South 
America has HIV epidemics with considerable subtype and CRF diversity including 
subtypes B, C, F and BF recombinant (Tebit et al., 2007) (Fig. 8).  
 
 
               
 
 
Fig.  8 Global distribution of HIV-1 subtypes and recombinants. Adapted from http://iavireport.org 
 
 
1.8 Brief background of HIV in Burkina Faso 
 Burkina Faso is a sub-Saharan country in West Africa with little information 
about HIV. HIV seroprevalence rates of 5-7% have been reported for the urban regions of 
this country (Meda et al., 2001; Simpore et al., 2004). HIV prevalence in Burkina Faso 
was estimated at 2% in 2005 (UNAIDS/WHO, 2007). An HIV prevalence of 3.6% has 
been reported for a rural area (Collenberg et al., 2006).  The first study on HIV genetic 
variability in this country by Ouedraogo-Traore et al., (2003) indicated CRF06_cpx as the 
dominant HIV strain in Ouagadougou, the capital city. However, recently we reported 
that the co-circulating dominant viruses in rural areas are CRF02_AG and CRF06.cpx 
(Tebit et al., 2006).  
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 The recent introduction of antiretroviral therapy in Burkina Faso necessitated two 
different types of studies. The first was to define the prevalence and resistance patterns in 
exposed patients failing therapy in Ouagadougou, Burkina Faso. NRTIs and NNRTIs 
constitute the first line of therapy in sub-Saharan Africa as well as in Burkina Faso. 
Accordingly, the prevalence of resistance-associated mutations in subjects failing 
HAART was 85% for NRTIs, 76% for NNRTIs, and 40% for PIs, corresponding to their 
respective usage (Tebit et al., 2008). The second study was aimed at screening drug naïve 
patients for the presence of drug resistance mutations. A high prevalence of NRTI and 
NNRTI resistance mutations of 10.6% and 6.1% respectively was observed (Tebit et al., 
2009). A similar prevalence of NRTIs (6%) and NNRTIs (11%) resistance mutations was 
observed among 17 naïve patients from another study in Ouagadougo, Burkina Faso 
(Nadembega et al., 2006). Drug resistance mutations occurred at similar frequencies 
among CRF02_AG (12.8%) and CRF06_cpx (10.8%) infected naïve subjects (Tebit et al., 
2009). 
 
 
 
Fig. 9 (A) Location of Burkina Faso in the Africa continent. (B) An enlarged view of Burkina Faso and 
its neighboring countries. The sampling areas (Nouna and Dedougou) are underlined. Adapted from 
http://100prozent-fuer-afrika.com and http://geography-site.co.uk 
 
 
1.9 Objectives of this study  
 Burkina Faso is one of the African countries where the current epidemic of HIV- 1 
is dominated by non-subtype B, particularly CRF02_AG and more than 50% of HIV-1 
B. A. 
Burkina Faso 
Nouna* 
Dedougou* 
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infected patients are women (UNAIDS/WHO, 2008). Since, most of HIV-1 infected 
mothers in this country still breast feed their infants and the extensively used of SD-NVP 
to prevent mother to child transmission, drug resistance variants might be possibly 
transmitted from infected mothers to their infants via breast feeding. Moreover, the 
availability of HAART for HIV-infected patients in Burkina Faso is becoming more 
accessible which may increase the emergence of drug resistant viruses. Therefore, the 
knowledge about the molecular genetics and phenotypic characteristics of HIV-1 
CRF02_AG from infected drug naïve individuals in Burkina Faso would provide 
important information prior to the introduction of large scale antiretroviral therapy or new 
classes of antiretroviral drugs. Moreover, development of a drug resistance assay would 
provide useful information for non-subtype B HIV-1 infected people in Africa where the 
number of individuals receiving antiretroviral therapy is increasing. 
 The overall aim of this study was to determine the genotypic and phenotypic 
characteristics of HIV-1 CRF02_AG strains from HIV-1 infected patients in Burkina 
Faso. The specific aims were: 
 i) To determine the polymorphisms and drug resistance mutations to the entry 
inhibitor enfuvirtide (T-20) among drug naïve subjects in rural Burkina Faso.  
 ii) To determine HIV resistance mutations in paired plasma and breast milk from 
HIV infected NVP-naïve and -exposed women by population sequencing and clonal 
analysis. Further, to analyze the diversity and evolution of HIV resistance using 
phylogenetic methods to compare the virus populations between plasma and breast milk 
from individual patients at both single and multiple time points. These analyses will 
establish whether HIV populations in plasma and breast milk in these women are 
compartmentalized.  
 iii) To investigate the phenotypic drug susceptibility of non-B subtypes based on a 
RVA using a similar genetic backbone like the viruses circulating in this region.  
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2. Materials and Methods 
2.1 Materials and instruments 
Material Manufacturer 
For biological methods  
Cell culture plate Orange Scientific, Belgium 
Dulbecco’s Modification of Eagle’s 
Minimum Essential Medium 
(DMEM) 
GIBCO® Invitrogen Cell Culture, Karlsruhe, Germany 
 
ELISA plates Maxisorb, Nunc, Wiesbaden, Germany 
Fetal calf serum (FCS) Biowest, Nuaillé, France 
Luciferase lysis buffer/substrate Steady-Glo®, #E2520, Promega, Mannheim Germany 
Luciferase plates Corning Costar #3912, 96 well plate, Fisher Scientific 
Roswell Park Memorial Institute 
1640 Medium (RPMI 1640) 
GIBCO® Invitrogen Cell Culture, Karlsruhe, Germany 
Trypsin 10x Trypsin/EDTA (0,5% / 0,2%), Biochrom AG, Berlin, 
Germany 
For molecular methods  
Agarose Agarose Serva, Heidelberg, Germany 
Cloning kit TOPO TA Cloning ® kit, Invitrogen, Karlsruhe, Germany 
DNA gel extraction kit Nucleospin® Extraction II, Macherey-Nagel, Düren, Germany 
Mutagenesis kit QuickChange II XL Site-Direct Mutagenesis Kit, Stratagene, La 
Jolla, CA. 
Plasmid purification kit QIAprep® Miniprep kit, QIAGEN, Hilden, Germany 
NucleoBond MaxiPrep Kit, Macherey-Nagel, Düren, Germany 
PCR amplification kit SuperScript™ III One-Step RT-PCR with Platinum® Taq DNA 
polymerase (RT-PCR), Invitrogen, Karlsruhe, Germany 
Expand High FidelityPlus PCR system (PCR for cloning), Roche, 
Mannheim, Germany 
PCR purification kit Qiaquick PCR purification kit (Qiagen, Hilden, Germany 
Nucleospin Extract II kit, Macherey-Nagel, Düren, Germany 
Restriction enzymes MBI Fermentas (St. Leon-Rot, Germany) 
New England BioLabs (Frankfurt a.M., Germany) 
Sequence analysis kit GenomeLab® Methods Development Kit, Beckman Coulter 
Ultrafiltration columns Vivaspin centrifugal concetrators (Vivaspin 6 and Vivaspin 20; 
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3 or 10 kDa), Sartorius AG, Göttingen, Germany 
viral DNA extraction kit DNeasy® Blood & Tissue kit, QIAGEN, Hilden, Germany 
Qiagen DNA extraction kit, QIAGEN, Hilden, Germany 
viral RNA extraction kit QIAmp® Viral RNA mini kit, QIAGEN, Hilden, Germany 
  
Instruments Manufacturer 
Centrifuges  
 
 
 
J2HC or J2HS with rotors JA-10, JA-17, JA-20, Beckman 
Coulter, Fullerton, CA, USA 
Eppendorf 5415D, Eppendorf Deutschland, Hamburg, Germany 
SIGMA 2K15, SIGMA Laborzentrifugen GmbH, Osterode am 
Harz, Germany 
Omnifuge 2.0 RS, Heraeus Sepatech 
DNA electrophoresis Mini-sub or wide mini-sub cell GT cell, Bio-Rad Laboratories 
GmbH, München, Germany 
ELISA reader spectrophotometric microplate reader, Dynatech, Enbrach, 
Switzerland 
Incubator Infors, Einsbach GmbH, Germany 
Luminescence reader Luminoskan Ascent, Thermo Labsystems, USA 
PCR thermocycler PTC-200 Peltier Thermalcycler, BioZyme, Oldendorf, Germany 
Sequencer machine CEQ-2000 sequencer, Beckman Coulter, CA, USA 
Spectrophotometer DU 640, Beckman Coulter, Fullerton, CA, USA 
Ultracentrifuge L8M or Optima XL-70, rotor SW-41 or SW-60 Ti, Beckman 
Coulter, Fullerton, CA, USA 
 
 
2.2 Media, buffers and reagents 
Name Concentrations  Recipe 
LB medium for bacteria culture 
 (1000 ml) 
 
1% peptone 
0.5% yeast extract 
171 mM NaCl 
10 g tryptone 
5 g yeast extract 
5 g NaCl 
0.5 ml 10 N NaOH 
pH 7.0; autoclaved 
 
LB agar for bacteria culture 
 
1.5% agar in LB medium 1000 ml  autoclaved LB medium 
15 g agar 
pour in sterile 10 cm dishes; store at 
4oC 
   
LB-ampicillin or kanamycin agar 
for bacteria culture 
 
100 μg/ml ampicillin or 
kanamycin 
1000 ml  autoclaved LB medium 
15 g agar  
100 mg ampicillin or kanamycin  
pour in sterile 10 cm dishes; store at 
4oC 
   
50x TAE buffer 
 (1000 ml) 
2 M Tris-acetate 
50 mM EDTA 
242 g Tris 
57 ml acetic acid 
100 ml 0.5 M EDTA pH 8.0 
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10x DNA loading buffer 
 (10 ml) 
100% glycerol 
2.5% bromphenol blue 
2.5% xylene cyanol 
10 ml glycerol 
0.25 g bromphenol blue 
0.25 g xylene cyanol 
 
 
10x Phosphate buffered saline 
(PBS) 
(1000 ml) 
1.37 M NaCl 
27 mM KCl 
80 mM Na2HPO4 
18 mM KH2PO4 
80 g NaCl 
2 g KCl 
14.4 g Na2HPO4.2H2O 
2.4 g KH2PO4 
   
10x PBST  
(1000 ml) 
10x PBS 
0.5% Tween 
1000 ml PBS 
5 ml Tween 
 
   
2x HeBS transfection buffer 
(1000 ml) 
280 mM NaCl 
50 mM HEPES 
1.5 mM Na2HPO4 
pH 7.09-7.12 
 
16.4 g NaCl 
11.9 g HEPES 
0.267 g Na2HPO4.2H2O 
filter sterilize through 0.45 µm pore 
size filters; store at 4°C 
 
2x CaCl2 transfection buffer 
(1000 ml) 
 
250 mM CaCl2 36.8 g CaCl2‧2H2O; 
filter sterilize through 0.45 µm pore 
size filters; store at 4°C 
 
2.3 Antiretroviral drugs 
The following reagents were obtained through the AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID.  
PIs: Lopinavir (LPV), Indinavir (IDV), Ritronavir (RTV), Tipranavir (TPV), 
Darunavir (DRV). 
NRTIs:  Zidovudine (AZT, ZDV), Dideoxyinosine (ddI), Stavudine (d4T), 
Lamivudine (3TC), Emtricitabine (FTC), Tenofovir (TDF).  
NNRTIs : Nevirapine (NVP), Efavirenz (EFV), Etravirine (ETR). 
 
2.4 Methods of biology  
 2.4.1 Ethical clearance for the study 
 In order to collect blood samples from HIV-infected individuals, an ethical 
clearance was obtained from the University of Heidelberg Ethics Committee, the Nouna 
Ethics Committee, and the Ministry of Health in Burkina Faso. 
  
 
  Materials and Methods 
 24 
 2.4.2 Sample collection  
 Three distinct sample sets for three different experiments were collected in this 
study. For screening of T-20 resistance related mutations, whole blood samples were 
obtained from HIV-positive pregnant women enrolled in the prevention of mother-to-
child transmission (PMTCT) program at the Nouna District Hospital, Nouna as well as 
from HIV-positive individuals presenting at the Dedougou Regional Hospital (DRH) in 
Dedougou, Burkina Faso between July 2003 and October 2004. At the time of sampling, 
all subjects were reported to be drug naïve (Tebit et al., 2006). The samples derived from 
HAART-exposed patients attending the University Teaching Hospital, Ouagadougou, 
Burkina Faso were used for phenotypic drug susceptibility assays. Samples for analyzing 
NVP resistance and compartmentalization consisted of plasma, breast milk and breast 
milk cells and were collected from NVP-exposed and –naïve women attending the 
PMTCT site in Nouna, Burkina Faso at different post delivery stages from 2004-2008.  
 The whole blood samples were collected in vacutainer tubes containing anti-
coagulants (EDTA). Afterwards, plasma and buffy coat were separated from the whole 
blood by centrifugation at 4,000 rpm for 15 minutes. Fifteen milliliters of breast milk was 
collected from lactating women in Falcon tubes and centrifuged at 1,500 rpm for 10 
minutes at 4oC to obtain the cellular, milk whey and lipid fractions. The samples were 
stored in aliquots at -80o C and shipped to Heidelberg later on dry ice. 
 
 2.4.3 CD4 count and viral load determination 
 The CD4 cell count was determined for whole blood up to 6 hours after collection 
using a FACScount fluorescence cytometer (Becton Dickinson, San Jose, CA) in Nouna, 
Burkina Faso. Plasma viral load was determined at the Virology Unit of the Center 
Hospital Universitaire Yalgado Ouedraogo (CHUYO) in Ouagadougou by using the 
Abbott RealTime HIV-1 assay with automated m2000 System (Abbott Molecular 
Diagnostics). Breast milk viral load was determined at the Department of Virology, 
University of Heidelberg after shipment by using the Amplicor HIV-1 monitor assay 
(Roche, Mannheim, Germany).  
 
 2.4.4 Cell culture 
 Two adherent cell lines (293T and TZM) and one suspension cell line (C8166) 
were used for phenotypic drug susceptibility assays in this study. 
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 293T is a highly transfectable human embryonic kidney cell line which was used 
for transfection experiments (Charneau et al., 1992). TZM (JC53BL) cells are derived 
from the HeLaP4 cell line. This cell type expresses CD4, CCR5 on their cell surface and 
carries genes for β-galactosidase and firefly luciferase under the control of the HIV-1 
LTR (Wei et al., 2002). This allows the measurent of HIV-1 infection by β-galactosidase 
or luciferase assays. The C8166 cell-line is a HTLV-I transformed human leukemia cell 
line highly susceptible to HIV-1 infection which forms syncytia after being infected 
(Salahuddin et al., 1983). 
 Adherent cells were maintained in DMEM (Dulbecco’s modified Eagle medium) 
high glucose (Gibco) containing 10% FCS (Biowest), 100 U/ml penicillin, 100 µg/ml 
streptomycin and 20 mM HEPES, pH 7.4. Cells were passaged after detachment with 
0.05% trypsin in PBS and then further cultivated in fresh medium. Suspension cells were 
cultivated in RPMI 1640 including the same supplements. All cells were incubated at 
37°C and 5% CO2 in a humid atmosphere. 
 
 2.4.5 Transfection of adherent cells with plasmid DNA 
Transfection was performed by using the standard calcium phosphate precipitation 
method (Chen and Okayama, 1987). 1 x 106 293T cells were seeded in a 10 cm culture 
dish and incubated overnight at 37°C, 5% CO2. On the next day, 10 µg of the plasmid 
DNA was mixed with 500 μl of 0.25 M CaCl2 and the same volume of 2x HeBS buffer 
(pH 7.09-7.12) was added during vortexing. After 15 minutes incubation at room 
temperature, this mixture was introduced drop-wise onto cells with gently swirling. 
Medium was changed about 6 or 16 hours post-transfection depending on the experiment. 
Virus particles in culture supernatant were harvested 48 hours after transfection and 
clarified by centrifugation at 1500 rpm for 5 minutes. The virus stocks were aliquoted and 
then stored at -80oC. 
 
2.4.6 Virus infectivity and replication kinetics 
To determine the viral infectivity, 5 x 103 TZM cells were infected in triplicate 
with the serial dilution of cleared viral supernatants in 96 well plates. TZM cells were 
lysed 48 hours after infection with the Steady-Glo® lysis buffer including luciferase 
substrate (#E2520; Promega, Mannheim Germany). The luciferase activity was measured 
with the Luminoskan Ascent luminometer (Thermo Labsystems). 
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To determine the replication kinetics of viruses, 5 x 105 C8166 cells were infected 
overnight with 50 ng of HIV-1 p24 antigen from the cleared viral supernatants. On the 
next day, cells were washed twice with PBS, re-suspended in 2 ml RPMI and maintained 
for 2 weeks. Culture supernatants were collected every 2-3 days for quantitative p24 
ELISA (described below in section 2.4.8) and an equal volume of fresh RPMI medium 
was added to the cultures (Garcia-Perez et al., 2008). 
 
 2.4.7 Drug susceptibility assays 
Drug susceptibility assay is adapted from Garcia-Perez et al. (2007). To determine 
the susceptibility to protease inhibitors (PIs), 293T cells were trypsinized at 
approximately 16 hours post-transfection and 5 x 104 cells were distributed into 48 well 
plates in the presence of serial PI dilutions in 500 μl total volumes. Viral stocks were 
harvested 48 hours after transfection and were used to infect 5 x 103 TZM cells in 
triplicate in 96 well plates in the absence of PIs.  
To measure the susceptibility to reverse transcriptase inhibitors (RTIs), viral 
stocks generated in the absence of drug were harvested 48 hours after transfection and 
were used to infect 5 x 103 TZM cells in triplicate using 96 well plates in the presence of 
increasing concentration of RTIs. 
Replication capacity of viruses in the presence or absence of antiviral drugs was 
monitored by measuring luciferase expression in infected TZM cells with the same 
procedure as described in section 2.4.6.  
 
2.4.8 Enzyme-linked immunosorbent assay (ELISA)  
 This ELISA is modified from Konvalinka et al. (1995). Ninety six well plates 
(Maxisorb, Nunc, Wiesbaden, Germany) were coated over night at room temperature in a 
moist chamber with 100 μl/well of monoclonal mouse-anti-CA antibody (183-H12-5C; 
diluted 1:1000 in PBS). Plates were washed and blocked with 10% FCS/PBS which 
prevents unspecific binding for 2 hours at 37°C. After washing, 100 μl of different diluted 
culture supernatants pre-treated with 0.1%Triton X-100 as well as dilution series of 
purified CA protein (6.25 – 0.1 ng/ml) were added to the plate and incubated overnight in 
a moist chamber at room temperature. On the following day, these plates were washed 
and incubated with rabbit-anti-CA antiserum (1:1000 in PBST/10% FCS) and 
subsequently with peroxidase-coupled goat-anti-rabbit antibody (1:2000 in PBST/10% 
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FCS) for 1 hour at 37°C each. The amount of bound antibody corresponding to p24 was 
revealed by adding the chromogenic enzyme substrate tetramethyl benzidine (TMB) for 5 
minutes. The reaction was stopped by adding sulfuric acid and the colored reaction 
product was quantified by measuring absorbance at 450 nm with a spectrophotometric 
microplate reader (Dynatech, Enbrach, Switzerland). 
 
 
2.5 Methods of molecular biology 
 2.5.1 Nucleic acid extraction from patient samples 
 Viral DNA was extracted from buffy coats and cellular fractions of breast milk by 
using the Qiagen DNA extraction kit (QAIGEN, Hilden, Germany) and DNeasy® Blood 
& Tissue kit (Qiagen, Hilden, Germany), respectively, following the manufacturer’s 
recommendations. Before the extraction, the breast milk cells were washed twice with 
PBS. 
 Viral RNA was extracted from 140 µl of plasma and 280 µl of breast milk using 
QIAmp® Viral RNA mini kit (QAIGEN, Hilden, Germany) according to the 
manufacturer’s instructions. If viral RNA from 280 μl of breast milk was not successfully 
extracted, the volume of breast milk was increased to 1 ml and centrifuged at 44,000 rpm 
at 4oC for 1 hour to precipitate the virus particles before the extraction procedure. 
 
 2.5.2 Polymerase Chain Reaction (PCR)  
 PCR allows the selective amplification of DNA sequences in presence of two 
specific oligonucleotide primers complementary to the 5’- and 3’- regions of the DNA 
molecule. All the primers used in this study are listed in Appendix 3. The amplification 
reagents and thermal cycling protocols used for PCR were chosen according to template 
and length of the fragment to be amplified (Appendix 4 and 5).  
 To obtain the PCR fragment from plasma sample, extracted RNA (section 2.5.1) 
was amplified with the SuperScript™ III One-Step RT-PCR with Platinum® Taq DNA 
polymerase (Invitrogen) as instructed by the manufacturer. For amplification of fragments 
less than 1 kb from DNA samples (section 2.5.1), PCR was performed with Taq 
polymerase, while long PCR fragments greater than 1 kb were generated with Expand 
High FidelityPlus PCR system (Roche, Mannheim, Germany) following the manufacturer’s 
instructions. 
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All PCR in this study were carried out in the PTC-200 Peltier Thermalcycler 
(BioZyme, Oldendorf, Germany). The PCR products were purified either with 
Nucleospin Extract II kit (Macherey-Nagel, Düren, Germany) or Qiaquick PCR 
purification kit (QAIGEN, Hilden, Germany). 
 
 2.5.3 Construction of CRF02_AG provirus backbone 
 To construct the CRF02_AG provirus plasmid backbone for phenotypic assay, the 
original pBD6-15 plasmid previously described in Tebit et al. (2003) was adapted to 
generate pBD6TB9 which was used for further modification as the parental plasmid. The 
initial step of plasmid modification was performed by knocking out an EcoRI restriction 
site at nucleotide (nt) position 4660 of the parental pBD6TB9 with primers listed in 
Appendix 3 by using the QuickChange II XL Site-Direct Mutagenesis Kit (Stratagene, La 
Jolla, CA), as instructed by the manufacturer.  
 A new EcoRI site was introduced at the beginning of the protease gene (nt 2242 of 
pBD6TB9) by PCR mutagenesis. In the first round PCR, the 5’ fragment (nt 1-2260 of 
pBD6TB9) and 3’ fragment (nt 2231-3555 of pBD6TB9) were amplified with Expand 
High FidelityPlus PCR system (Roche, Mannheim, Germany). In the second round, the 
purified 5’ fragments (2.2 kb) and 3’ fragments (1.3 kb) from first round PCR were used 
as the template. In this step, the 5’ and 3’ fragments were ligated via the overlapping 
region and generated the 3.5 kb final PCR products.  
 The constituents of the PCR reaction and the cycling conditions are listed in 
Appendix 4 and 5.  
 
2.5.4 Re-amplification of protease and reverse transcriptase (PR-
 RT) fragments for phenotypic assays 
 Determination of drug resistance mutations (genotypic test) was performed by 
amplifying the PR-RT region with the ViroSeq HIV-1 Genotyping System (Applied 
Biosystems) as recommended by manufacturer. This amplification step was performed by 
the diagnostic section, Department of Virology, Heidelberg University. PCR products 
from these analyses were kept at -20 oC and were re-amplified with Expand High 
FidelityPlus PCR system (Roche, Mannheim, Germany) to obtain the 1.3 kb of patient 
derived PR-RT coding sequences with the primers, reaction components and cycling 
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conditions listed in Appendix 3-5. The 1.3 kb PR-RT fragment from HIV-1 subtype B, 
pNL4-3 was also amplified by the same procedure. 
 
 2.5.5 Restriction digest and ligation 
 2.5.5.1 DNA cleavage with restriction enzymes 
 All enzymes and buffers for DNA cloning and restriction digest were from MBI 
Fermentas (St. Leon-Rot, Germany) or from New England BioLabs (Frankfurt a.M., 
Germany). For a control restriction digest, approximately 1-2 µg DNA was incubated 
with 10 U restriction enzyme in a volume of 20 µl at the recommended temperature. For 
further cloning purposes, 2-20 μg of plasmid or 30 µl purified PCR product was digested 
with 20 U of specific restriction enzyme in a volume of 50-100 µl. 
  
 2.5.5.2 TA cloning vector 
 Taq polymerase has a non-template dependent terminal transferase activity which 
adds a single deoxyadenosine (A) to the 3’end of PCR product. This activity facilitates 
the cloning of Taq amplified fragments into a commercially available linearized vector 
pCR®2.1 TOPO supplied with the TOPO TA Cloning ® kit (Invitrogen, Karlsruhe, 
Germany). This vector has single overhanging 3’ deoxythymidine (T) residues together 
with topoisomerase activity which allows PCR fragments to efficiently ligate with the 
vector. The ligation was performed following the manufacturer’s instruction and 
subsequently used to transform competent bacteria provided with the kit. Fifteen clones 
per sample were selected for sequencing analysis.  
 
 2.5.5.3 Ligation of PR-RT fragments into circularised vector 
 To generate the new vector backbone for phenotypic assay, the 3.5 kb PCR 
fragments (section 2.5.3) were digested with ApaI and Stu I (MBI Fermentas, St. Leon-
Rot, Germany) and were subsequently ligated to pBD6TB9 parental plasmid digested 
with the same enzymes, providing the final plasmid “pBD6TB9RI”. To generate the 
patients-derived recombinant plasmids and chimeric CRF02_AG/subtype B plasmid, the 
1.3 kb PR-RT fragments (section 2.5.4) were digested with EcoRI and StuI and ligated 
into the EcoRI – StuI digested pBD6TB9RI backbone. About 5 to 50 ng of vector was 
ligated with DNA fragments in a 1:5 molar ratio and in a total volume of 20 μl with 2 
units of T4 DNA ligase and incubated at 16oC overnight. In all ligation experiments, a 
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control reaction composed of only vector was included. Competent bacteria were 
transformed with 5-10 μl ligation reaction. 
 
 2.5.6 DNA electrophoresis and isolation of DNA fragments 
 DNA electrophoresis was used for the analysis of PCR products, or purified 
restriction digested DNA fragments. Depending on the size of the DNA fragment to be 
purified, 1–1.5% (w/v) agarose in TAE buffer was melted by heating, 2 µg/ml 
ethidiumbromide was added and the gel was poured into the gel tray and cooled down. 
DNA samples mixed with DNA loading buffer were loaded onto the gel and resolved for 
40 minutes at 90 volt. DNA bands were detected with UV light of 312 nm or of 366 nm to 
avoid DNA damage for further cloning steps. The fragment size was estimated by 
comparison with the DNA 1 kb ladder marker on the same gel. Bands of the correct size 
were cut out and purified with the NucleoSpin® Extract kit (Macherey-Nagel, Düren, 
Germany).  
 
 2.5.7 Sequencing analyses 
 Sequence analysis of RT fragments and plasmid DNA was performed in-house 
based on the dye terminator method by using GenomeLab® Methods Development Kit 
on a CEQ-2000 sequencer (Beckman Coulter, CA, USA). For sequencing reactions,50 
fmol of plasmid DNA, 1.6 µM primers (Appendix 3) and manufacturer’s premix solution 
(containing DNA polymerase, dNTPs, labeled ddNTPs, buffer) were used to amplify the 
DNA fragment of interest in a total volume 20µl. After that, the reaction was stopped and 
DNA fragments generated by the reaction were precipitated by adding 5 µl stop-solution 
(3 M NaAc pH 5.2, 100 mM EDTA pH 8.0 and glycogen). The pellet was washed once 
with absolute ethanol and then with 70% ethanol, air-dried and re-dissolved in 40 µl of 
sample loading solution providing with the kit (Beckman Coulter, CA, USA). The 
dissolved DNA was transferred to a 96-well plate and overlaid with mineral oil to prevent 
evaporation.  
 All DNA samples after March 2008 were commercially sequenced by GATC 
Biotech (Konstanz, Germany).  
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 2.5.8 Bacteria transformation and plasmid DNA preparation  
 2.5.8.1 Bacteria strains 
 For transformation experiment with the pCR®2.1-TOPO both E. coli strain DH5α 
(Invitrogen) with the genotype F- θ80lacZΔM15 Δ(lacZYA-argF)U169 deoR recA1 
endA1 hsdR17(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 λ-  and TOP10 competent 
bacteria with the genotype F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15ΔlacX74 
recA1 araD139 Δ(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG, supplied with the 
TOPO TA cloning kit ((Invitrogen), were used. In the case of proviral plasmid 
preparation, MAX Efficiency® Stbl2TM Competent Cells (Invitrogen) were used since this 
E. coli strain shows particularly few recombination events. Stbl2TM bacteria are derived 
from JM109 strain and the genotype is: F– mcrA Δ(mcrBC-hsdRMS-mrr) recA1 endA1 
lon gyrA96 thi supE44 relA1 λ– Δ(lac-proAB). 
 
 2.5.8.2 Transformation 
 Bacteria were transformed using the standard heat-shock procedure. 
Approximately 150 ng (1-2 µl) of plasmids or 10 ligation reactions were added to 50 µl of 
chemically competent bacteria (DH5α, TOP10 or Stbl2). The mixture was incubated for 
20 minutes on ice, heated for 30-45 seconds at 42°C and then cooled on ice for 2 minutes 
and 500µl of antibiotic-free LB was added. The transformed bacteria were incubated in a 
shaker incubator (200 rpm) at 37°C for 1 hour. The bacteria was spread on an LB plate 
containing ampicillin or kanamycin and incubated over night at 37°C. Single colonies 
were randomly picked to inoculate 2 ml and 200 ml of LB medium containing ampicillin 
or kanamycin for small and large amounts plasmid DNA preparations, respectively.  
 
 2.5.8.3 Preparation of small amounts of plasmid DNA (mini-preparation)  
 Mini-preparation of plasmid DNA was performed using the QIAprep® Miniprep 
kit (QAIGEN, Hilden, Germany). Bacteria culture was pelleted for 3 minutes at 
5,000 rpm and resuspended in 250 µl P1 buffer. Bacteria were lysed by addition of 250 µl 
P2 buffer, and the reaction was stopped by neutralization with 350 µl N3 buffer. The cell 
debris was pelleted for 10 minutes at 13,000 rpm and supernatant was subsequently 
applied to spin column and centrifuged 13,000 rpm for 30 seconds. The column was 
washed twice with 750 µl of PE buffer and plasmid DNA was eluted with 50 µl of EB 
buffer. All preparation steps were carried out at room temperature. 
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 2.5.8.4 Preparation of large amounts of plasmid DNA (maxi-preparation) 
 Maxi-preparation of plasmid was performed by using NucleoBond® Maxiprep kit 
(Macherey-Nagel, Düren, Germany). The bacteria was resuspended, lysed and neutralized 
by using buffer S1, S3 and S3, respectively. The supernatant containing plasmid DNA 
was loaded onto Nucleobond® column pre-wet with buffer N3, subsequently washed 
with buffer N4 and plasmid DNA was eluted from the column with buffer N5. Purified 
plasmid DNA was then precipitated with isopropanol and washed with 70% ethanol. 
Plasmid DNA was dried at room temperature and re-dissolved in water. 
 
 
2.6 Bioinformatical methods and analysis 
 2.6.1 Identifying drug resistance mutations   
 Sequence editing was performed using the program Vector NTI Advance™ 10 
(Invitrogen, Karlsruhe, Germany). The resistance mutations in PR (codon 1-99), RT 
(codons 1-250) and gp41 were determined by using the Drug Resistance Algorithm from 
the Stanford HIV drug Resistance Database (http://hivdb6.stanford.edu). This tool 
compares the input sequences with sequences of HIV-1 subtype B in the database which 
confer resistance to anti-HIV drugs. 
 
 2.6.2 Phylogenetic analyses, viral diversity and divergence 
 Sequences of HIV-1 RT fragments were aligned with Clustal X 2.0.6 (Larkin et 
al., 2007) with the reference sequences of major HIV-1 subtypes available from the Los 
Alamos HIV sequence database (http://hiv-web.lanl.gov) with minor manual adjustments. 
All alignments were gap-stripped for the generation of trees. Phylogenetic analyses were 
performed with MEGA 4 (Tamura et al., 2007) by using neighbor joining with the 
Kimura’s two parameter (K2P) method and 1,000 bootstrap resamplings of the data. 
Maximum likelihood trees were also constructed using the PHYLIP 3.67 (Felsenstein, 
1989).  Evolutionary distances between sequences were determined by calculating the 
mean pair wise genetic distances among all sequences from individual patients at each 
time point with MEGA 4 using the K2P model with transition/tranversion ratio of 2.0 
(Leitner et al., 1996; Becquart et al., 2007; Gottlieb et al., 2008).  
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 Viral divergences were measured as the pair wise genetic distances of all clones at 
a given time point to the bulk sequence at the first time point (most recent common 
ancestor, MRCA) for each patient (Troyer et al., 2005). 
 
 
2.7 Statistical analyses 
 To determine possible differences in viral load between plasma and breast milk 
and to verify whether the time after SD-NVP exposure influenced compartmentalization, 
statistical analyses were performed using the Mann-Whitney test. Differences in the 
genetic diversity and divergence of viruses between plasma, breast milk and/or breast 
milk cells were performed using the Wilcoxon signed rank test or Kruskal-Wallis test 
with Dunn's Multiple Comparison post-test. 
To measure virus susceptibility to various antiretroviral drugs, the inhibition 
percentage was calculated using the following formula (Garcia-Perez et al., 2007); 
   1001% 

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
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

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I , 
where %I is an inhibitory percentage, RLUp is a luciferase activity in the presence of 
drug and RLUa is a luciferase activity in the absence of drug. 
 The dose-response curves were obtained by plotting the percent inhibition versus 
log10 of drug concentration. The 50% inhibitory concentration (IC50) of each drug was 
computed by nonlinear regression curve using a sigmoidal dose-response equation with 
the GraphPad Prism5 software (version 5.02). The fold changes in susceptibility were 
calculated by dividing the IC50 of the mutant virus by IC50 of wild type virus. Results 
were expressed as the mean value, standard error of mean (SEM), and coefficient of 
variation (CV) of 3 to 4 independent experiments. To determine possible differences in 
IC50, statistical analysis was performed by using the Friedman test with Dunn’s multiple 
comparison post-test. The p-values below 0.05 were considered to be statistically 
significant. 
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3 Results 
 3.1 Genotypic resistance to enfuvirtide (T-20)  
 T-20 drug resistance–associated polymorphisms were determined in the HR1 and 
HR2 sequences of gp41 from 38 naïve HIV infected patients consisting of HIV-infected 
individuals from Dedougou regional hospital (DRH) and pregnant women who enrolled 
in the PMTCT program in Nouna which was implemented in 2003.  
 The CD4 values among pregnant women ranged from 93-747 cells/μl, whereas 
CD4 counts of patients from DRH ranged from 1-718 cells/μl. The viral load was in range 
from 103 to 106 copies/ml which is generally high as expected from HIV-drug naïve 
patients (Tebit et al., 2006). The genotypes obtained were as follows: CRF02_AG (55%), 
CRF06_cpx (45%) and other subtypes e.g. CRF09_cpx and A3 (5%) (Tebit et al., 2006). 
 As demonstrated in figure 10, in the HR1 region, the GIV motif which is 
primarily responsible for T-20 resistance was conserved among all sequences. The most 
common polymorphism observed within this region was N42S (n = 36) which was 
dominant among CRF02_AG and CRF06_cpx viruses (Fig. 10). The Q56K/R 
polymorphism was found among sub-subtype A3, CRF02_AG, and CRF09_cpx viruses, 
but not in CRF06_cpx viruses (Fig 10). The combination L54M/Q56K was observed in 
three sequences of CRF02_AG and one of CRF06_cpx viruses (Fig. 10).  
 Ten amino acids in HR2 at position 117, 120, 123, 127, 131, 134, 138, 141, 145 
and 148 are known to be involved in the sensitivity to T-20. Six of the ten amino acids at 
positions 120, 127, 131, 134, 141 and 145 were totally conserved in all strains (Fig. 10). 
Meanwhile, S138A (n = 4) was the most common polymorphism found among the 
remaining four non-conserved amino acid positions. The polymorphisms N126K (n = 3), 
N126S (n = 1) and N140I (n =3) were also detected in HR2 sequences. Generally, the 
amino acid sequence of the HR2 region was more heterogeneous compared with that of 
the HR1 region (Fig. 10). 
 
 
  Results 
 35 
 
                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HR1                                     HR2 
aa    32                                                 82         112                                                  163 
HxB2  QLLSGIVQQQNNLLRAI.EAQQHLLQLTVWGIKQLQARILAVERYLKDQQLL          WNHTT..WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFN 
 
A3 
A061  -----------------.----Q--K------------V-------------          -ENM-..-LQ--K--S---DT-YG-LQ---Y-------D--A----T------D 
 
CRF02_AG 
A101  ----------S------.-------K------------V--L----R-----          -DNM-..-LQ--K--S----I-YN--------------D--A----T------D 
A368  --W-------S---N--.-------K------------V--L----R-----          -ENM-..-L---K--SK-SGT-YT------K------LD--A----SN-----G 
A395  ----------S---K--.-----M-K------------V--L----R-----         --NM-..-QQ--K------E--Y-----------T---D--A-----------S 
A450  ----------S---K--.-------K------------V--L----R-----         -ENM-..-LQ--K-VS---DI-YN-L-N----------D--A--------D--- 
A461  --------------K--.-----M-K------------V--L----R-----         -DNM-..-LQ--K------NI-YG-L------------D--A-----------D 
A465  ----------S---K--.-------R------------V--L----------         -DNM-..-LQ--K--S---DT-YR------I-------D--A--------S--D 
A543  ----------S---Q--.-----M-R------------V--L----T-----         -KNM-..-LQ--K------NI-YD--------------D--A------------ 
A675  ----------S------.----Q--K------------V--L-S--R-----         --NM-..-LQ--K--S---QK-YN-L------------D--A-----N--T--D 
A696  ----------S---K--.-----M-R------------V--L----------         -DNM-..-IQ-E---D---DT-Y--L------------D--A-----------S 
A758  ----------S------.-----M-K------------V-------------         -GNM-..--Q---------QQ-YN-----------------S--------S--D 
A1035 ----------S---K--.----N--K------------V--L----------         -GNM-..-LQ-EK--D---GT-YE---N------I--RD--A-----------D 
NR46  ----------S------.----Q--K------------V--L-S--R-----         -DNM-..-L---K--S---NI-YE-------------KD--A-----------D 
D001  ----------S------.-------K------------V--L-A--R-----         -ENM-..-LQ--K------DI-YQ------L---R---D--A-----------D 
D006  ----------S---K--.-------K------------V--L-S--------         -ANM-..-LQ--K-----SEI-YD------R--D----D--A----T---S--S 
D040  ---------HS---K--IQ--H---K------------V--L----------         -DNM-..-LQ--K-VS---DI-YT-L------------D--A-----N------ 
D043  --W-------S---K--.-----M-R------------V--L----------         -ENM-..-L--E---S---DT-YT---KAH------------------------ 
 
CRF06_cpx 
A123  ----------S------.--------------------V--L----R-----         --NM-..-I------D---QY-YT------T----------A-----------D 
A216  ----------S------.--------------------V--L----R-----  --NM-..-I------D---QY-Y----------D----D--A--------S--D 
A401  ----------S------.--------------------V--L----R-----  --NM-..-I----------QY-Y----------D----D--A-----------D 
A421  ----------S------.-V------------------V-------G-----  --NM-..-IQ-----D---QE-YN---K------Q---D--A------------ 
A435  ----------S---S--.--------------------V-------------  -DNM-..-IQ---------QQ-YR---K-------------A--E--------D 
A468  ----------S------.--------------------V--L----R-----  -GNM-..--Q---------QQ-YN-----------------S--------S--D 
A762  ----------S---S--.--------------------V--L----------  GDNM-..RIQ------K--QQ-Y--MK---I---------WA----PTVN..GL 
A1123 ----------S------.--------------------L-------------  -DNM-..-K----------Q--Y-------I-------D--AW-------S--D 
N001  ----------S------.--------------------V--L----R-----  --NM-..-I----------QY-Y----------D----D--A-----------D 
N202  H---------S------.--------------------V-------R-----  -GNM-..-IQ-----DS--QE-YN---K------Q------AW-------D--- 
D003  ----------S------.--------------------V-------------  -DNM-..-I----------QQ-Y----IA-T-------D--A--Q-TN--S--S 
D004  ----------S------.--------------------V-------------  -DNM-..-IQ--K------QQ-YN---Q--S-------D--A--Q-S------D 
D008  ----------S------.--------------------V-------R-----  -DNM-..-I----------Q--Y-------T-------D--A----S---S--D 
D010  ----------S------.--------------------V-------------  -DNMETT-I----------QQ-YN----A-T-------D--AW----------D 
D012  ----------S------.--------------------V-------R-----  -DNM-..-IQ-----D---QH-YN-LA---T-------D--A--Q--------D 
D038  --W-------S------.--------------------V--L----------  -DNM-..-IQ---------QQ-YT--------------D--A--------S--D 
D039  --M-------S------.-----M--------------V-------------  -DNM-..-IQ-E---G---QE-YD-L-K-------------A----D---S--- 
D041  ----------S---K--.--------------------V--L----------  --NM-..-I---K--S---QQ-Y---------------D--A--------S-YD 
D042  ----------S------.--------------------V--L----R-----  -DNM-..-IQ-E-------EQ-YN-L----T-------D--A----T---S—S 
 
CRF09_cpx 
D007  ----------S---Q--.-------K------------V-------------  -DNM-..-L------S---QI-YR--------------D--A--S-----S--D 
D009  ----------S---M--.-----M-K------------V--L----------  -ANM-..-LQ-E----K--HT-YE----A---------D--A--S--N-----G 
Fig 10. Alignment 
of T-20 resistance 
mutations in HR1 
and HR2 regions of 
gp41 of 38 HIV-1 
infected-patients 
(Italic). HXB2 is the 
HIV-1 subtype B 
strain. The amino 
acid (aa) positions 
associated with T-20 
resistance were 
underlined.  dot (.) = 
deletion; dash (-) = 
amino acid identity. 
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3.2 NVP resistance mutations in paired plasma-breast milk 
 3.2.1 Patients and Clinical data 
 Fifty three selected HIV infected breast feeding women, who have enrolled in 
PMTCT programe in Nouna, provided paired plasma and breast milk samples for this 
study. However, RNA or DNA could be derived from both plasma and breast milk or 
breast milk cells of 17 women (Table 3). Five women provided two samples, while one 
woman provided three samples at different time points respectively (Table 3).  
 Of the 17 women, 10 received SD-NVP at labor and only one received a drug 
combination comprising AZT at week 28 of pregnancy, single dose of NVP+AZT+3TC 
at labor and AZT+3TC at 7 days post delivery, which is the new regimen for PMTCT 
recommended by the Ministry of Health in Burkina Faso. Six women were drug naïve 
because they did not receive SD-NVP at labor (Table 3). The average CD4+ cell count pre 
and post delivery was 355 and 438 cells/mm3 respectively. The plasma viral load ranged 
between 500 to 500,000 copies/ml (average = 165,025 copies/ml). The viral load in breast 
milk was significantly lower than in plasma (Mann-Whitney test, p = 0.0001) with a mean 
of 4,498 copies/ml ranging between <40 to 44,603 copies/ml (Table 3). 
 
Table 3. Clinical characteristics of patients who provided plasma and breast milk samples 
 
Viral load 
(copies/ml) 
ID 
 
 
Age at 
baseline 
Drug 
regimen 
Subtype CD4 pre-
delivery 
(cells/mm3) 
CD4 post-
delivery 
(cells/mm3) 
Time of 
sampling 
(mo/yr) PL BM 
A368 
 
30 SD-NVP 02_AG 280 
 
157 
 
-/04 
-/05 
786,242 
344,000 
760 
ND 
A401 
 
23 SD-NVP 06_cpx 277 
 
216 
 
-/04 
-/05 
261,999 
72,997 
4,000 
<40 
A435 28 SD-NVP 02_AG 377 217 -/04 586,635 85 
A465 29 SD-NVP 02_AG 615 ND -/04 141,000 893 
ABa249 
 
32 new 
regimena 
02_AG 487 
 
654 
 
11/07 557 
 
ND 
 
ABk162 34 SD-NVP 06_cpx 260 341 06/07 4,493 440 
ADb169 
 
23 SD-NVP 02_AG ND 
 
473  
559  
11/07 
04/08 
ND 
ND 
216 
69 
AGn031 
 
28 
 
SD-NVP 06_cpx 287 
 
523  
 
04/07 
10/07 
163,996 
ND 
<40 
NDc 
ASn079 33 SD-NVP 02_AG 425 325  05/08 78,267 15,068 
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Table 3. Clinical characteristics of patients who provided plasma and breast milk samples 
(continued) 
 
Viral load 
(copies/ml) 
ID 
 
 
Age at 
baseline 
Drug 
regimen 
Subtype CD4 pre-
delivery 
(cells/mm3) 
CD4 post-
delivery 
(cells/mm3) 
Time of 
sampling 
(mo/yr) PL BM 
AY113 23 SD-NVP 06_cpx ND 418 02/08 1,946 NDc 
AY134 
 
 
31 
 
SD-NVP 02_AG ND 
 
 
802  
621   
560  
02/07 
07/07 
02/08 
2,069 
20,726 
4,461 
NDc 
NDc 
120 
ABm107 33 naïveb  02_AG ND 432  01/08 5,993 119 
ADb365  30 naïveb 02_AG 425 379 01/08 4,457 44,603 
ADr304  25 naïveb 06_cpx 290 633   04/08 1,667 NDc 
AGg078  32 naïveb 06_cpx 117 359 11/07 89,754 NDc 
AGn006  22 naïveb 02_AG ND 432 03/07 35,924 975 
AY172  
 
28 naïveb 02_AG 417 
 
441  
369  
06/07 
08/07 
1,810 
1,268 
<40 
NDc 
 
a = combination regimen (AZT at week 28 of pregnancy, single dose of NVP+AZT+3TC at labor and 
AZT+3TC at 7 days post delivery); b = did not receive SD-NVP at labor; c = PCR positive in breast milk 
cells; SD-NVP = single dose Nevirapine; PL = plasma; BM = breast milk; ND = not done; mo = month; yr 
= year. 
 
 
3.2.2 Genotypic drug resistance in NVP –naïve and exposed women  
 3.2.2.1 Subtype classification 
 To determine the distribution of HIV-1 subtypes that are circulating among HIV-
infected pregnant women in Nouna, rural Burkina Faso, the BM and plasma samples were 
PCR amplified and sequenced. The bulk sequences of the 5’ RT region spanning about 
950 bp from 24 samples of 17 HIV infected women were aligned with reference subtype 
sequences from the Los Alamos Database and a phylogenetic tree was constructed using 
maximum likelihood method as implemented in the Phylip 3.67 program. HIV sequences 
from eleven women (64.7%) clustered with HIV-1 CRF02_AG (Fig. 11), HIV isolates 
from six women (35.3%) were closely related with CRF06_cpx (Fig. 11). Plasma, breast 
milk and/or breast milk cells sequences from the same patients clustered together (Fig. 
11). 
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Fig. 11 Phylogenetic tree of pol region of the 17 HIV-1 infected women from Nouna, Burkina Faso 
(Italic). The tree was generated using the maximum likelihood method by PHYLIP 3.67 program. 
Reference sequences were obtained from the Los Alamos HIV database. The tree was rooted using HIV-1 
subtype O as an outgroup. Subtypes are indicated to the right.  
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 3.2.2.2 NVP-resistance mutations detected by direct /clonal sequencing 
 3.2.2.2.1 Direct sequencing 
 A genotypic drug resistance test based on direct PCR-product sequencing has 
been widely used to detect drug resistance mutations in HIV-1 infected patients. 
However, a major limitation of direct sequencing is that it does not detect variants which 
comprise less than 20% of sequences in the virus population (Palmer et al. 2005). As 
demonstrated in figure 12, direct sequencing of PCR products of the RT-region from 
patient-ABK162 indicates the presence of two different populations as observed from 
double peaks at the nucleotide position 541 in the electropherogram (top panel and 
arrow). However, the nucleotide G is the higher peak and so is detected as the dominant 
population. In contrast, when individual clones of this RT-fragment were analyzed, both 
distinct nucleotides were detected in this position which shows that the sample contains 
two groups of viruses (Fig. 12; middle and bottom panels).   
 
 
Fig. 12 Electropherograms 
of RT fragment from patient 
ABK162. Top panel is a 
sequence derived from direct 
sequencing representing two 
different nucleotides at the 
same position (double peak and 
arrow). Middle and bottom 
panels demonstrate the 
sequences from individual 
clonal analysis. The two 
different nucleotides are 
indicated by arrows. 
 
 
 
 
 
 
 
 
 
 
 
 
Direct sequencing 
Clonal analysis: 
individual clone # 1 
Clonal analysis: 
individual clone # 2 
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 Two major NVP-resistance mutations, K103N and Y181C, were detected in 
paired plasma-breast milk samples from two NVP-exposed women by direct sequencing 
(Table 4). Amino acid substitution at position 179 (V179E) which slightly reduces 
susceptibility to all drugs in NNRTI group was detected in paired samples from one NVP-
exposed woman at both sampling time points (Table 4).  
 Some NRTI resistance mutations were detected among NVP-naïve and exposed 
women with no NRTI history. The M184I mutation which decreases 3TC, ABC and FTC 
susceptibility was observed from breast milk cells of one NVP-exposed woman (Table 4). 
Moreover, another NRTI resistance mutation, E44D, was found in one NVP-naïve 
woman (Table 4). Although, E44D mutation alone does not substantially alter NRTIs 
susceptibility, this mutation could correspondingly increase cross-resistance to other 
NRTIs in the presence of Thymidine Analogue-associated mutations (TAMs) (Walter et 
al., 2002).   
 
Table 4.  Drug resistance mutations detected by direct sequencing and clonal analysis 
 
Direct sequencing Clonal analysis 
  
ID 
 
 
Day 
post-
delivery PL BM BMc PL (n) BM (n) BMc (n) 
A368/1** 
 
 
 
180 
 
 
 
K103N 
 
 
 
WT 
 
 
 
K103N 
 
 
 
WT (2)  
K103N (11) 
K103N + M230V(1) 
K238Q (1) 
WT (13)  
K103N (1) 
F227L (1) 
 
K103N (15) 
K103N+Y181C (1) 
 
 
A368/2# 
 
360 
 
WT 
 
NA 
 
NA 
 
WT (14)  
K103N (1) 
NA 
 
NA 
 
A401/1*** 
 
 
210 
 
 
WT 
 
 
WT 
 
 
NA 
 
 
WT (13)  
P225S + F227C (1) 
F227C (1) 
WT (13) 
L100W (1) 
G190E (1) 
NA 
 
 
A401/2# 390 WT NA NA WT (15)  NA NA 
A435*** 
 
 
150 
 
 
WT 
 
WT 
 
WT 
 
WT (13) 
K103N (2) 
 
WT (8) 
K103N (6) 
K103E (1) 
WT (14) 
K65R (1) 
K65R+ K219E (1) 
A465*** - WT WT NA WT (15) WT (15) NA 
ABa249*** 0 WT WT NA WT (15) WT (15) NA 
ABk162* 
 
 
 
 
10 
 
 
 
 
Y181C 
 
 
 
 
Y181C 
 
 
 
 
G190R + 
(M41I+M184I) 
 
 
 
WT (5) 
Y181C (6) 
Y188C (3) 
K103R + Y181C(1) 
M230L (1) 
WT (9) 
Y181C (7) 
 
 
 
G190R+ (M41I + 
M184I) (15) 
V106A+G190R + 
(M41I + M184I) (1) 
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Table 4. Drug resistance mutations detected by direct sequencing and clonal sequencing 
(continued). 
Direct sequencing Clonal analysis 
  
ID 
 
 
Day 
post-
delivery 
PL BM BMc PL (n) BM (n) BMc (n) 
ADb169/1*** 180 V179E V179E NA V179E (13) V179E (15) NA 
ADb169/2* 
 
330 
 
V179E 
 
V179E 
 
NA 
 
V179E (14) 
 
V179E (15) 
V179G (1) 
NA 
 
AGn031/1* 
 
 
3 
 
 
WT 
 
 
WT 
 
 
NA 
 
 
WT (13) 
V108A (2) 
 
WT (13) 
K101E (1) 
K103R (1) 
NA 
 
 
AGn031/2* 
 
180 
 
WT 
 
NA 
 
WT 
 
WT (14) 
G190A (1) 
NA 
 
WT (16) 
 
ASn079* 
 
2 
 
WT 
 
WT 
 
WT 
 
WT (15) 
G190R (1) 
WT (16) 
 
WT (15) 
 
AY113* 
 
360 
 
WT 
 
NA 
 
A98T 
 
WT (15) 
 
NA 
 
A98T (15) 
A98T + K219R (1) 
AY134/1* 
 
7 
 
WT 
 
NA 
 
WT 
 
WT (14) 
V179L (1) 
NA 
 
WT (14) 
Y188H (1) 
AY134/2*** 
 
 
210 
 
 
WT 
 
 
NA 
 
 
WT 
 
 
WT (14) 
K130N (1) 
L100S (1) 
NA  
 
 
WT (9) 
V179T (6) 
K103R +V179T(1) 
AY134/3*** 360 WT WT NA WT (16) WT (15) NA 
ABm107*** 
 
 
30 
 
 
WT 
 
 
WT 
 
 
NA 
 
 
WT (16) 
 
 
WT (14) 
V106A (1) 
A98T (1) 
NA 
 
 
ADb365*** 21 WT WT NA WT (15) WT (16) NA 
ADr304* 
 
180 
 
WT 
 
NA 
 
WT 
 
WT (13) 
V118I (1) 
NA 
 
WT (16) 
 
AGg078* 
 
 
AGn006* 
 
2 
 
 
435 
 
E44D 
 
 
WT 
 
NA 
 
 
WT 
 
E44D 
 
 
WT 
 
WT (2) 
E44D (13) 
E44D + P225L (1) 
WT (15) 
 
NA 
 
 
WT (14) 
V108I (1) 
E44D (12) 
 
 
WT (14) 
F227L (1) 
AY172/1* 120 WT NA WT WT (15) NA WT (15) 
AY172/2*** 
 
180 
 
WT 
 
WT 
 
NA 
 
WT (14) 
 
WT (13) 
V179A (1) 
NA 
 
 
PL = Plasma; BM = Breast milk; BMc = Breast milk cells; WT = wild type; NA = not amplified; Bold = 
high level resistance to NVP (NNRTI); Bold-underline = cross resistance mutation to ETR (NNRTI); 
underline = polymorphism or mutations associated with modest NNRTIs resistance; Bold-Italic = high 
level resistance to NRTIs; Italic = polymorphism or mutations associated with modest NRTIs resistance;  
* = compartmentalization; ** = partial-compartmentalization; *** = non-compartmentilzation; # = not 
analyzed for compartmentalization. 
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 3.2.2.2.2 Clonal analyses 
 Using the same PCR products as for the direct sequencing, the RT fragments were 
cloned in a TA vector and more than 10 clones per sample were sequenced. The 
mutations associated with high level resistance to NVP were detected in 11 of 24 cases 
(46%) as major or minor variants by clonal analyses (Table 4). Besides the major 
mutations, other mutations which slightly reduce NVP susceptibility as well as some 
polymorphisms were also found mostly as minor population (Table 4). The most common 
mutations among NVP-exposed women were at positions 103 and 179 (Fig. 13; Table 4). 
Mutations at position 103 included K103N, K103E, K103T and K103R with N being the 
most common, constituting about 70% of all 103 mutants. Sequences carrying both the 
K103N/R and Y181C mutations were extremely rare. Only two patients carried this 
double mutation; one had K103N+Y181C, while the K103R+Y181C mutations were 
observed in the other (Table 4). Some other mutations such as K101E, G190A and 
Y188C/H were found as minor variants (Table 4). 
 NRTI resistance mutations were also detected by clonal analysis. The K65R 
mutant was detected only in breast milk cells of patient-A435 as a small proportion (2 of 
15 clones; Table 4). However, it was absent in plasma and breast milk. In patient-
ABK162, the M184I mutation was again found in breast milk cells as the dominant 
population (16 of 16 clones; Table 4).  
 From NVP-naïve women, NVP resistance mutations such as V106A, V108I were 
found in low proportions which were undetectable by direct sequencing of the PCR 
population products (Table 4). Moreover, the NRTI mutation, E44D which could be 
detected by direct sequencing was also present as the dominant population in plasma (13 
of 15 clones) and breast milk cells (12 of 12 clones) in one patient (Table 4).  
 In summary, mutations associated with high level resistance to NVP were detected 
in only 8% of patients by direct sequencing, while the detection rate increased to 46% by 
clonal analysis (Table 4). This finding suggests that the clonal analysis reveals a higher 
prevalence of NVP resistance mutations than direct sequencing. 
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 Fig. 13 NVP resistance mutations detected in plasma (PL), breast milk (BM) and breast milk cells (BMc) among patients by clonal analysis.  
 NRTIs* = mutations to nucleoside reverse transcriptase inhibitors, NNRTIs* = mutations to non- nucleoside reverse transcriptase inhibitors.  
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 3.2.2.3 Persistence of NVP resistance associated mutations 
 To determine the persistence of resistance variants over time, clonal analysis was 
performed from two paired plasma-breast milk samples obtained from two subjects 
(A368, and ADb169) and two paired plasma-breast milk cells samples from one subject 
(AY134) at different time points after delivery (Table 3). In A368, sampling was done at 
respectively, six and twelve months post delivery (Table 3). As expected, in this patient, 
the proportion of viruses containing NVP resistance mutation K103N declined over time. 
This mutation which represented the dominant population (detected in 11 of 15 plasma 
clones) at six months post delivery nearly disappeared from the virus population (detected 
in 1 of 15 plasma clones) after twelve months post delivery (Table 4). However, the 
V179E mutation detected from patient ADb169 which causes low level reduction in 
NNRTI susceptibility persisted as a dominant population in plasma and breast milk, 
although the patient received NVP almost eleven months prior to sampling (Table 4). It 
is, however, possible that this mutation occurred as wild type in this subject even pre-SD 
NVP administration. In patient AY134, NVP resistance mutations such as K103N as well 
as other polymorphisms which have been detected at seven months post-NVP exposure 
completely disappeared at twelve months (Table 4). 
 
 3.2.3 Phylogenetic analyses  
 3.2.3.1 Viral distribution and compartmentalization 
 To determine the distribution of the variants from the various compartments, the 
clonal and population sequences were aligned and phylogenetic trees constructed. To 
obtain phylogenetic trees from individual patients, both Neighbor-Joining (NJ) and 
Maximum-likelihood (ML) trees were constructed by programs MEGA4.0 and PHYLIP 
3.67, respectively. The obtained trees were grouped into three categories, i.e. 
compartmentalized, partially-compartmentalized and non-compartmentalized trees. A tree 
is defined as compartmentalized, if the sequences between plasma and breast milk or 
breast milk cells sampled at the same time point are completely segregated. If a cluster of 
sequences sampled at the same time point either from breast milk or breast milk cells is 
not completely distinguished from plasma, this type of clustering is defined as partial-
compartmentalization. Finally, if individual sequences from samples collected at the same 
time point from plasma, breast milk and/or breast milk cells mix with each other, this tree 
is classified as non-compartmentalized. From 24 samples, only 22 paired samples could 
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be used for sequence analysis. In two samples namely A368/2 and A401/2, no PCR 
products could be obtained from either breast milk or breast milk cells (Table 4).  
 Compartmentalization was observed in eleven cases, seven of these were from 
NVP-exposed and four from NVP-naïve patients (Table 4; Fig. 14A - 14K). Partial-
compartmentalization was found in only one NVP-exposed woman (Table 4; Fig. 15A) 
and non-compartmentalization presented in ten cases, seven and three cases from NVP-
exposed and NVP-naïve patients respectively (Table 4; Fig. 15B - 15K).  
  Most of the samples which were used for phylogenetic analysis were either paired 
plasma-breast milk or plasma-breast milk cells. However, a complete set of sequences 
including plasma, breast milk and breast milk cells at a single time point could be 
obtained from four NVP-exposed and one NVP-naïve women. Viral populations between 
breast milk and breast milk cells were segregated in 4 cases: ABK162 (Fig. 14A), 
ASn079 (Fig. 14B), AGn006 (Fig. 14C) and A368/1 (Fig. 15A), but not for A435 (Fig. 
15B). Statistical analysis showed that time after receiving SD-NVP did not have any 
significant effect on compartmentalization [Mann-Whitney test, p = 0.6746, n 
(compartment) = 11, n (non-compartment) = 10]. 
 
 3.2.3.2 Viral heterogeneity  
 The diversity of HIV variants may be influenced by the environment in which 
they evolve. Thus, the paired samples from two patients, ADb169 and AY134 were 
analyzed for their viral heterogeneity in plasma and breast milk or breast milk cells at two 
different time points. The time interval between the first and second sampling was 
approximately five to seven months.  
 The phylogenetic tree of patient-ADb169 at the first time point showed that the 
virus population in breast milk was separated into 2 clusters (Fig. 16A). Almost all of the 
breast milk clones (10 of 15 clones) were genetically distinct from the plasma clones, 
whereas a small proportion of breast milk variants (5 of 15 clones) were genetically 
closely relate to the major virus population in plasma. The tree of patient-ADb169 at the 
second time point showed that the virus population in breast milk was completely 
separate from the virus population in plasma (Fig. 16A). For patient-AY134, virus 
population in breast milk cells from this patient at the first time point was completely 
separate from virus population in plasma, whereas at the second time point viruses in 
breast milk cells were inter-mix with the plasma viruses (Fig. 16B). 
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Fig. 14 Maximum-likelihood (ML) 
phylogenetic trees of pol sequences 
from plasma (PL), breast milk (BM), 
and breast milk cells (BMc) at 
different time points representing 
compartmentalization of A) ABK162 
(NVP-exposed), B) ASn079(NVP-
exposed), C) AGn006 (NVP-naïve), 
D)AGn031/1(NVP-exposed), E) 
AGn031/2 (NVP-exposed), F) 
AY134/1 (NVP-exposed), G) 
ADb169/2 (NVP-exposed), H) 
AY113 (NVP-exposed), (I) ADr304 
(NVP-naïve), J) AGg078 (NVP-
naïve), K) AY172/1 (NVP-naïve). 
Close squares, close circles and 
close triangles represent sequences 
from PL, BM and BMc respectively 
at first time point. Open squares, 
open circles and open triangles 
represent sequences from PL, BM 
and BMc respectively at second time 
point. Asterisks represent sequences 
harboring resistance mutation. 
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Fig. 15 Maximum-likelihood (ML) 
phylogenetic trees of pol sequences 
from plasma (PL), breast milk (BM), 
and breast milk cells (BMc) at 
different time points representing of 
partial-compartmentalization of A) 
A368 (NVP-exposed) and non-
compartmentalization of B) A435 
(NVP-exposed), C) A401/1 (NVP-
exposed), D) A465 (NVP-exposed), 
E) Aba249 (NVP-exposed), F) 
ADb169/1 (NVP-exposed), G) 
AY134/2 (NVP-exposed), H) 
AY134/3 (NVP-exposed), (I) 
ABm107 (NVP-naïve), J) ADb365 
(NVP-naïve), K) AY172/2 (NVP-
naïve). Close squares, close circles 
and close triangles represent 
sequences from PL, BM and BMc 
respectively at first time point. Open 
squares, open circles and open 
triangles represent sequences from 
PL, BM and BMc respectively at 
second time point. Open and close 
diamonds represent sequences from 
PL and BM respectively at third time 
point. Asterisks represent sequences 
harboring resistance mutation. 
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 A.         1st time point    2nd time point  
        
 B.         1st time point    2nd time point 
          
 
Fig. 16  Maximum-likelihood phylogenetic trees of pol sequences from plasma, and breast milk or breast 
milk cells  representing (A) patient ADb169 sequences at the first and second time point and (B) patient 
AY134 sequences at the first and second time point. Close squares, close circles and close triangles 
represent respectively sequences from plasma, breast milk and breast milk cells at the first time point. Open 
squares, open circles and open triangles represent respectively sequences from plasma, breast milk and 
breast milk cells at the second time point. Asterisks represent sequences harboring drug resistance. 
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 3.2.4 Evolution of HIV-1 in different anatomic compartments 
 3.2.4.1 Genetic diversity 
 To determine the genetic diversity of the virus in plasma, breast milk and breast 
milk cells, evolutionary distances were calculated as the mean pair wise distance among 
all clones from individual patients. The difference in evolutionary distances of sequences 
between the two groups e.g. plasma-breast milk, plasma-breast milk cells or breast milk-
breast milk cells was statistically tested by Wilcoxon signed rank test, and by Kruskal-
Wallis test with Dunn's Multiple Comparison post-test for three types of sequences e.g. 
plasma-breast milk-breast milk cells. 
 The results showed that the genetic diversity of plasma variants was significantly 
higher than the breast milk variants in nine of fifteen (60%) paired samples (Table 5).  
This observation was also found in paired plasma and breast milk cells samples where 
nine of twelve (75%) plasma sequences showed significantly higher genetic diversity than 
those from breast milk cells. In comparison to variants in breast milk and breast milk 
cells, only two of five (40%) of breast milk sequences showed a significantly higher 
genetic diversity than the variants from breast milk cells (Table 5).  
 The level of genetic diversity of variants derived from the complete sample set 
consisting of plasma, breast milk and breast milk cells within individual patients was 
calculated. From four NVP-exposed patients (A368, ABK162, Asn079 and A435) and 
one NVP-naïve patient (Agn006), the genetic distances of plasma variants was the highest 
compared to variants obtained from breast milk or breast milk cells (Fig. 17A - 17D). 
There was a wide distribution of breast milk variants in one case, A435 forming two main 
clusters (Fig. 17E). In general, variants from breast milk cells were much more 
homogenous than those in breast milk and plasma. 
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Fig. 17 Evolutionary distance between variants in plasma (PL), breast milk (BM) and breast milk cells (BMc) from individual patients at single time point representing the 
genetic diversity of (A) A368, (B) ABK162, (C) Agn006, (D) Asn079 and (E) A435. Close squares, close circles and close triangles represent mean distance in PL, BM and 
BMc sequences respectively. Scatter plots show median, p-values are from nonparametric, Kruskal-Wallis test with Dunn's Multiple Comparison post-test. 
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Table 5. Genetic diversity of HIV variants from PL, BM, and BMc represented as mean pair wise distances 
ID 
Mean pair wise distance at 
1st time point  
Mean pair wise distance at 
2nd time point  
Mean pair wise distance at 
3rd time point  
  PL BM BMc p-value PL BM BMc p-value PL BM BMc p-value 
A368 0.0223 0.0139 0.0051 PL-BM > 0.05b 0.0129 - - ND - - - ND 
    PL-BMc < 0.001b         
    BM-BMc < 0.05b         
             
A401 0.0132 0.0106 - 0.2483a 0.0059 - - ND - - - ND 
             
A435 0.0149 0.0359 0.0095 PL-BM < 0.01b - - - ND - - - ND 
    PL-BMc > 0.05b         
    BM-BMc < 0.001b         
             
A465 0.0148 0.0121 - 0.0184a - - - ND - - - ND 
             
ABa249 0.0051 0.0133 - 0.0007a - - - ND - - - ND 
             
ABK162 0.0171 0.0038 0.0015 PL-BM < 0.001b - - - ND - - - ND 
    PL-BMc < 0.001b         
    BM-BMc > 0.05b         
             
ADb169 0.0057 0.0039 - 0.3659
a 0.0083 0.0010 - 0.0011a - - - ND 
             
AGn031 0.0139 0.0081 - 0.0041a 0.0175 - 0.0006 0.0007a - - - ND 
             
ASn079 0.0096 0.0008 0.0037 PL-BM < 0.001b - - - ND - - - ND 
    PL-BMc < 0.001b         
    BM-BMc > 0.05b         
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Table 5. Genetic diversity of HIV variants from PL, BM, and BMc represented as mean pair wise distances (continued) 
ID 
Mean pair wise distance at 
1st time point  
Mean pair wise distance at 
2nd time point  
Mean pair wise distance at 
3rd time point  
  PL BM BMc p-value PL BM BMc p-value PL BM BMc p-value 
AY113 0.0065 - 0.0011 0.0007a - - - ND - - - ND 
             
AY134 0.0031 - 0.0025 0.2575a 0.0053 - 0.0059 0.2296a 0.0063 0.0015 - 0.0011a 
             
ABm107 0.0086 0.0092 - 0.2053
a - - - ND - - - ND 
             
ADb365 0.0061 0.0070 - 0.4540
a - - - ND - - - ND 
             
ADr304 0.0044 - 0.0004 0.0024a - - - ND - - - ND 
             
AGg078 0.0136 - 0.0011 0.0024a - - - ND - - - ND 
             
AGn006 0.0090 0.0035 0.0029 PL-BM < 0.001b - - - ND - - - ND 
    PL-BMc < 0.001b         
    BM-BMc > 0.05b         
             
AY172 0.0076 - 0.0014 0.0010a 0.0071 0.0076 -  0.8011
a - - - ND 
             
 
a = nonparametric (Wilcoxon signed rank test); b = nonparametric (Kruskal-Wallis test with Dunn's Multiple Comparison post-test). 
Bold = statistically significant; ND = not determined; PL = Plasma; BM = Breast milk; BMc = Breast milk cells. 
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 3.2.4.2 Genetic divergence 
 Longitudinal sampling of four NVP-exposed patients (A368, ADb169, AGn031, 
and AY134) and one NVP-naïve patient (AY172) were available for determining the 
genetic divergence of viruses. Viral divergences were measured as the pair wise genetic 
distances of all clones at a given time point compared to the bulk sequence at the first 
time point (most recent common ancestor- MRCA) for each patient.  
 In plasma, five of six cases had no significant difference (p > 0.05) in genetic 
divergence between the first and second time points, with an exception of sequences from 
patient A401 which showed a significant difference in genetic divergence (p = 0.0378) 
between the first and second time points (Table 6). However, in subject AY134, there 
were no significant differences in the divergence of plasma variants between the first and 
second, or the second and third time points, but there was a significant difference between 
the first and third time points (Fig. 18A; Table 6). In breast milk (ADb169; Table 6) and 
breast milk cells (AY134, Fig. 18B; Table 6) between the first and second time points, 
significant differences in genetic divergence were observed in both cases (Table 6).  
 Overall, the genetic divergence in plasma increased with time in four of six 
women, but only two of them were statistically significant (Table 6), whereas in breast 
milk and breast milk cells, the genetic divergence significantly increased with time in 
both cases (Table 6). 
 
 
 
Fig. 18 Level of genetic divergence of plasma (PL) and breast milk cells (BMc) sequences at different 
time points represented by scatter plots. (A) Divergence of PL sequences at 3 time points from patient 
AY134, (B) divergence of BMc sequences at 2 time points from patient AY134. Close squares, open 
squares and open diamonds represent distance in plasma sequences at first, second and third time points 
respectively. Close triangles and open triangles represent mean distance in breast milk cells sequences at 
first and second time points respectively. MRCA = most recent common ancestor (bulk sequence at first 
time point). Scatter plots show median, p-values are from nonparametric, Kruskal-Wallis test with Dunn's 
Multiple Comparison post-test or Wilcoxon signed rank test. 
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 Table 6. Genetic divergence of HIV variants from plasma (PL), breast milk (BM), and breast milk cells (BMc) at different time points 
 
 
Genetic divergence  
from MRCA (mean)   
Genetic divergence 
from MRCA (mean)  
Genetic divergence 
from MRCA (mean)  
 PL1 PL2 PL3 p-value BM1 BM2 p-value BMc1 BMc2 p-value 
A368 0.0218 0.0167 - 0.0554a - - - - - - 
           
A401 0.0132 0.0093 - 0.0378a - - - - - - 
           
ADb169 0.0057 0.0066 - 0.5325a 0.0039 0.0108 0.0011a - - - 
           
AGn031 0.0139 0.0195 - 0.0545a - - - -   - 
           
AY134 
 
 
0.0034 
 
 
0.0053 
 
 
0.0073 
 
 
PL1-2 > 0.05b 
PL1-3 < 0.01b 
PL2-3 > 0.05b - - - 
0.0025 
 
 
0.0134 
 
 
0.0007a 
 
 
           
AY172 0.0076 0.0093 - 0.2708a - - - - - - 
 
  PL1, PL2, PL3 = plasma at the first, second and third time points respectively; 
  BM1, BM2= breast milk at the first and second time points respectively; 
  BMc1, BMc2 = breast milk cells at the first and second time points respectively; 
  a = nonparametric (Wilcoxon signed rank test); b = nonparametric (Kruskal-Wallis test with Dunn's Multiple Comparison post-test); 
  Bold = statistically significant; MRCA = most recent common ancestor. 
 
  Results 
 55 
3.3 Phenotypic characterization of a CRF02_AG based 
plasmid backbone  
3.3.1. Construction and validation of a CRF02_AG based plasmid 
 backbone 
To better understand the influence of a non-subtype B plasmid backbone on 
recombinant viral assays, the infectious molecular clone pBD6TB9 was modified by 
knocking out an EcoRI restriction site (nucleotide position 4460). After that a new EcoRI 
site was introduced at the beginning of the protease gene (nucleotide position 2242) to 
generate pBD6TB9RI (Fig. 19). To clone the patient-derived PR-RT fragments into 
pBD6TB9RI, the newly introduced EcoRI site and a StuI restriction site present in the 
reverse transcriptase gene were used. The modifed and parental plasmids were transfected 
into 293T cells and their supernatants were used to infect C8166 cells for measuring 
replication kinetics or TZM cells for testing viral infectivity. 
 
Fig. 19 Schematic representation of pBD6TB9RI. Amplified PR and RT fragment from patients are 
inserted into an indicator vector by using EcoRI and StuI restriction sites. 
 
 
The replication kinetics of the viruses generated from the new plasmid backbone 
pBD6TB9RI was measured by comparing the level of p24 production from C8166 
infected cells to the parental molecular clone pBD6TB9. The virus produced from the 
newly constructed pBD6TB9RI displayed similar replication kinetics to its parental virus 
shown by a comparable level of p24 production as observed in the figure 20A. 
Luciferase activity produced from the TZM-infected cells was measured to 
evaluate the viral infectivity of viruses produced from pBD6TB9RI and parental 
pBD6TB9. As demonstrated in the figure 20B, the infectivity of both viruses was similar. 
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Fig. 20 (A) Replication kinetics of parental BD6TB9 virus (solid line) compared to the modified BD6TB9RI virus (dash line). C8166 cells were infected with equal 
amounts of p24 and virus replication measured by quantifying HIV-1 p24 (ng/ml) production in culture supernatant during 2 weeks. (B) Viral infectivity between 
parental BD6TB9 virus (dark gray bar) and modified BD6TB9RI virus (white bar) were measured. TZM cells were infected with BD6TB9 or BD6TB9RI viruses and 
luciferase activity was detected in cell lysates 48 hours after infection. 
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3.3.2 Effect of the CRF02_AG derived plasmid backbone on 
 susceptibility to antiretroviral drugs 
To evaluate the drug susceptibility profile of the CRF02_AG recombinant plasmid 
pBD6TB9RI backbone, and its effect on the antiretroviral drug susceptibility, a chimeric 
virus was generated by cloning the PR-RT fragment derived from the pNL4-3 into 
pBD6TB9RI, hereafter named BD6TB9RINL. The susceptibility profiles of the viruses 
were determined by adding serial dilutions of PIs to transfected cells or RTIs to infected 
cells. Drugs that inhibit virus replication should reduce luciferase activity in dose-
dependent manner, and this provides a quantitative measure of drug susceptibility. 
Inhibition of luciferase activity was plotted against drug concentration (log10) for each 
tested drug.  Drug susceptibility fold changes were determined by comparing IC50 of 
tested virus with the IC50 of the control virus.  
The phenotypic drug susceptibility profiles for BD6TB9RI (wild type 
CRF02_AG), BD6TB9RINL chimera and NL4-3 (wild type B) are shown in the figure 21 
and Table 7. These three viruses revealed similar drug susceptibility profiles to all RTIs. 
The susceptibility profiles to PIs among these three viruses were also similar. However, 
they exhibited differences in susceptibility against two PIs: ritonavir (RTV) and tipranavir 
(TPV). There was a difference in the drug concentration fold change for RTV (>2.5-fold) 
for chimeric BD6TB9RINL and NL4-3 viruses respectively compared to wild type 
BD6TB9RI virus (Table 7). For TPV, there was also a >2.5-fold change difference for 
NL4-3 compared to wild type BD6TB9RI (Table 7).  
The IC50 of RTV and TPV of the BD6TB9RI virus was lower than for the 
chimeric BD6TBRINL and NL4-3 viruses shown by a shift to the left of the dose-
response curves (Fig. 21). The dose-response curves of RTV and TPV of 
theBD6TB9RINL chimera which contained the PR-RT fragment from NL4-3, subtype B 
virus, was closely similar to NL4-3 (Fig. 21). To confirm the observed differences, a 
statistical analysis was performed to determine differences in IC50 values of RTV and 
TPV between these three viruses by using the Friedman test with Dunn’s multiple 
comparison post-test. The BD6TB9RI virus produced from the CRF02_AG plasmid 
showed no significant difference in IC50 to both PIs compared to chimeric BD6TB9RINL 
and NL4-3 viruses (p>0.05). 
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Fig. 21 Phenotypic drug susceptibility to the PR and RT inhibitors representing CRF02_AG wild type virus (BD6TB9RI, black solid line), CRF02_AG/subtype B 
chimera (BD6TB9RINL, dash line) and subtype B virus (NL4-3, gray solid line). The dose-response curves were obtained by plotting the inhibition percentage versus 
the log10 of drug concentration. The IC50 was calculated by nonlinear regression curve. The error bars indicated means ± SEM. Changes in drug susceptibility were 
determined by dividing the IC50 of test virus by the IC50 of the wild type (WT). 
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Table 7.  Drug susceptibility fold change of the CRF02_AG/subtype B chimera (BD6TB9RINL), subtype B (NL4-3) viruses in comparison 
to CRF02_AG wild type virus (BD6TB9RI) 
 
    Fold change in susceptibility  (IC50 for test virus/IC50 for control virus) 
a 
 Resistance mutations detected by genotypic test PIs    NRTIs   NNRTIs 
Sample PIs NRTIs NNRTIs LPV IDV DRV RTV TPV   AZT d4T 3TC ddI FTC TDF   NVP EFV ETR 
BD6TB9RINLb none none none 2.5 1.1 1.1 3.2 2.2  0.7 1.1 1.1 1.0 1.0 1.6  2.4 1.6 1.3 
                    
NL4-3c none none none 1.9 1.4 1.1 2.7 2.9   1.7 1.5 0.7 1.2 0.6 2.0   1.2 1.5 1.2 
 
a = fold change was calculated as the IC50 ratio between the sample and the control virus (BD6TB9RI) that was tested in the same experiment; 
b = Chimeric virus 
[plasmid contained PR and RT region from pNL4-3 (subtype B) and backbone from pBD6 (CRF02_AG)]; c = Subtype B virus. 
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3.3.3 Phenotypic drug susceptibility testing with patient-derived  
 recombinant viruses 
3.3.3.1 General information of patient-derived recombinant viruses 
 For phenotypic drug susceptibility assays, the sample set was collected from 75 
HAART-exposed HIV-infected patients presenting at CHUYO in Ouagadougou from 
2004-2006 (Tebit et al., 2008). The range of CD4 counts was between 2-469 cell/mm3 
and viral load ranged from 1 x 103 to 4 x 106 copies/ml (Tebit et al., 2008). Recombinant 
viruses in this present study were generated by cloning a 1.3 kb PR-RT fragment re-
amplified from five patient-derived PCR products used previously for genotypic assays 
(Tebit et al., 2008) into the pBD6TB9RI plasmid backbone. These five selected patients 
were infected with HIV-1 CRF02_AG, received different antiretroviral drugs regimens 
and showed distinct resistance mutation patterns (Table 8).  
 Individual clones carrying different drug resistance mutations were randomly 
picked from recombinant libraries. Sequence analyses confirmed that there were no 
differences in the PR and RT mutations between the original patient samples and the 
corresponding recombinant viruses (Table 9). 
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Table 8.  Clinical data and drug resistance mutation patterns derived from genotypic analysis 
 
         
 
Drug resistance mutations by sequence analysis (genotypic assays) 
ID Sex Age VLa CD4b 
Current 
regimen 
Past  
regimen Subtype Resistance status PIs NRTIs NNRTIs 
120 
 
F 
 
53 
 
61,996 
 
5 
 
3TC-AZT-IDV 
 
none 
 
CRF02.AG 
 
+/-PI, +/-NRTI 
 
 
M46I, L76V, I84V, 
L10I, E35G, Q58E 
M41L, E44D, D67N, V118I, 
M184V, L210W, T215Y, K219N 
K101Q, E138K 
 
            
127 M 47 333,000 173 AZT- ddI none CRF02.AG +/-NRTI none M41L, T215Y none 
            
228 
 
M 
 
9 
 
25,000 
 
59 
 
3TC-d4T-NVP 
 
none 
 
CRF02.AG 
 
+/-NRTI,+/-NNRTI 
 
none 
 
K65R, T69D, K219R 
 
K101Q, Y181C, Y188CY, 
G190A 
            
273 
 
M 
 
-  
 
43,000 
 
-  
 
-  
 
none 
 
CRF02.AG 
 
+/-NRTI 
 
none 
 
M41L, M184V, L210W,  
T215Y, K219W 
A98G 
 
            
41 
 
F 
 
41 
 
1,120,000 
 
22 
 
3TC-d4T-IDV 
 
none 
 
CRF02.AG 
 
+/-PI, +/-NRTI,+/-NNRTI 
 
M46I, I84V, L10I 
 
M41l, D67HN, T69NT, M184V, 
T215Y 
K103KN 
 
            
 
a = viral load (copies/ml); b = cells/mm3; PI = protease inhibitors; NRTI = nucleoside reverse transcriptase inhibitors; NNRTIs = non-nucleoside reverse transcriptase 
inhibitors; Bold = mutations at position associated with drug resistance; Italic = minor resistance mutations to protease inhibitors. 
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Table 9.  Comparison of amino acid substitutions in PR and RT between original patient samples and the corresponding recombinant viruses 
 
  Amino acid at the following positions 
Sample Source PIs  NRTIs  NNRTIs 
    L10 E35 M46 Q58 L76 I84 L89   M41 E44 K65 D67 T69 V118 M184 L210 T215 K219  A98 K101 K103 E138 Y181 Y188 G190 
120 Originala I G I E V V   L D  N  I V W Y N   Q  K    
 Recombinantb  I G I E V V   L D  N  I V W Y N   Q  K    
                            
127 Originala         L        Y          
 Recombinantb         L        Y          
                            
228 Originala           R  D     R   Q   C C/Y A 
 Recombinantb          R  D     R   H   C  A 
                            
273 Originala       V  L      V W F W  G       
 Recombinantb       V  L      V W F W  G       
                            
41 Originala I  I  V V   L   H/N N/T  V  Y     K/N     
 Recombinantb  I  I  V V   L   N   V  Y     N     
                                                        
 
Bold = mutations in positions associated with resistance to protease (PIs) and reverse transcriptase (NRTI, NNRTI) inhibitors; Italic = minor resistance mutations to protease 
inhibitors; a = original patient plasma samples used for genotypic assay (direct sequencing); b = individual clones randomly selected from recombinant libraries (clonal 
analyses). 
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 3.3.3.2 Phenotypic drug susceptibility profiles of patients-derived 
 recombinant  viruses  
 The phenotypic drug susceptibilities of these recombinant viruses carrying 
patient-derived PR-RT coding sequences were analyzed as outlined in section 3.3.3.1. 
Representative results of susceptibility folds change are presented in Table 10 and are 
explained below. 
 
Table 10.  Drug susceptibility fold change of the patient-derived recombinant viruses in 
comparison to CRF02_AG wild type virus (BD6TB9RI) 
 
 Fold change in susceptibility  (IC50 for test virus/IC50 for control virus)a 
 PIs    NRTIs   NNRTIs 
Sample LPV IDV DRV RTV TPV   AZT d4T 3TC ddI FTC TDF   NVP EFV ETR 
BD6TB9RI120b 31.4 29.8 1.8 14.3 1.8  72.5 5.0 >500 4.5 >100 7.3  1.7 0.9 1.4 
                 
BD6TB9RI127b 5.3 1.1 1.1 2.3 1.2  9.6 2.3 2.0 1.6 1.7 2.9  0.7 0.3 0.2 
                 
BD6TB9RI228b 0.4 0.4 0.4 0.3 0.1  0.3 3.1 29.8 4.9 24.6 4.6  >125 416.9 12.8 
                 
BD6TB9RI273b 0.9 0.5 0.9 0.6 0.3  62.6 2.0 >150 1.6 >100 2.3  0.2 0.2 0.5 
                 
BD6TB9RI41b 33.2 7.3 0.9 6.0 0.2  2.7 2.1 >300 3.3 >100 2.1  48.5 12.0 0.2 
 
a = fold change was calculated as the IC50 ratio between the sample and the control virus (BD6TB9RI) that 
was tested in the same experiment; b = patient-derived recombinant viruses. 
 
 
 (i) BD6TB9RI120; the patient who provided this sample had been treated with the 
combination of 3TC, AZT and IDV and harbored the mutations with highly decreased 
susceptibility to PIs and NRTIs (Table 8). The susceptibility profile obtained from this 
recombinant virus is in agreement with the therapeutic history (Fig. 22). This recombinant 
virus was resistant to three protease inhibitors; LPV (31-fold), IDV (30-fold) and RTV 
(14.3-fold) (Fig. 22; Table 10) but was susceptible to protease inhibitors; DRV (1.8-fold) 
and TPV (1.8-fold) (Table 10). Due to the accumulation of multi-nRTI resistance mainly 
with thymidine analogue-associated mutations (TAMs) such as M41L, D67N, L210W,  
and T215Y which affect all currently approved NRTIs, this recombinant virus was highly 
resistant to all tested NRTIs in this experiment (Fig. 22; Table 10). The amino acid 
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substitutions at positions K101Q and E138K in RT gene which were earlier reported to 
cause low level resistance to NNRTIs by genotypic testing were observed although this 
patient was NNRTIs naïve (Table 10). However, this recombinant virus was shown to be 
susceptible to NNRTIs by phenotypic testing (Fig. 22; Table 10). 
 
 (ii) BD6TB9RI127; this sample was from a patient who received a combination of 
AZT and ddI and harbored mutations to NRTIs (Table 8). Low level resistance to AZT 
accompanied by d4T cross resistance and ddI accompanied by TDF cross resistance was 
detected by the phynotypic assay (Fig. 23; Table 10). 
 
 (iii) BD6TB9RI228; was obtained from a patient treated with 3TC, d4T and NVP 
combination regimen (Table 8). An increase in fold resistance was detected in all tested 
NRTIs (Fig. 24; Table 10). However, this recombinant virus was susceptible to AZT due 
to the presence of the K65R mutation which causes AZT hypersusceptibility (Fig. 24; 
Table 10). Several NNRTIs resistance mutations e.g. K101Q, Y181C, Y188C/Y, and 
G190A were observed due to the NVP-exposure. These mutations induced cross 
resistance to all NNRTIs including ETR, the newly approved NNRTI (Fig. 24; Table 10). 
 
 (iv) BD6TB9RI273; this sample was from a patient with unavailable treatment 
history (Table 8). This recombinant virus carried several mutations to NRTIs such as 
M184V and three TAMs: M41L, L210W, and T215Y when analyzed genotypically. As 
expected, the intermediate to high level resistance to NRTIs was detected (Fig. 25; Table 
10). This recombinant virus remained susceptible to NNRTIs, although the substitution at 
position A98G which has been shown to possibly affect ETR susceptibility (Johnson et 
al., 2008) was detected (Fig. 25; Table 10). One minor resistance mutation to PIs, L98V, 
was found but did not alter the susceptible to PIs used in this experiment (Fig. 25; Table 
10). 
 
 (v) BD6TB9RI41; this sample was derived from a patient with documented use of 
the combination therapy of 3TC, d4T and IDV (Table 8). The phenotypic assay 
demonstrated its resistance to three PIs; LPV (33-fold), IDV (7-fold) and RTV (6-fold) 
(Fig. 26; Table 10). In contrast, this recombinant virus was susceptible and 
hypersusceptible to the PIs, DRV (0.9-fold) and TPV (0.2-fold) respectively (Fig. 26; 
Table 10). High level resistance as well as cross resistance to NRTIs was detected which 
is in agreement with the patient’s therapeutic history (Fig. 26; Table 10). The mutation 
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K103N, which confers high level resistance to EFV and NVP but not ETR (Jonnson et al., 
2008) was detected in this recombinant virus despite the patient’s non exposure to 
NNRTI. The resistance profile showed an intermediate to high level resistance to EFV 
(12-fold) and NVP (49-fold), but remained susceptible for ETR (0.2-fold) (Fig. 26; Table 
10).  
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Fig. 22 Phenotypic drug susceptibility to PR and RT inhibitors representing the CRF02_AG wild type virus (BD6TB9RI, solid line) and the patient-derived PR-RT 
recombinant virus (BD6TB9RI120, dash line). The dose-response curves were obtained by plotting the inhibition percentage versus the log10 of drug concentration. The IC50 
was calculated and is illustrated by a nonlinear regression curve. The error bars indicate means ± SEM. Changes in drug susceptibility were determined by dividing the IC50 
of the test sample by the IC50 of the wild type (WT). 
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Fig. 23 Phenotypic drug susceptibility to PR and RT inhibitors representing the CRF02_AG wild type virus (BD6TB9RI, solid line) and the patient-derived PR-RT 
recombinant virus (BD6TB9RI127, dash line). The dose-response curves were obtained by plotting the inhibition percentage versus the log10 of drug concentration. The IC50 
was calculated and is illustrated by a nonlinear regression curve. The error bars indicate means ± SEM. Changes in drug susceptibility were determined by dividing the IC50 
of the test sample by the IC50 of the wild type (WT). 
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Fig. 24 Phenotypic drug susceptibility to PR and RT inhibitors representing the CRF02_AG wild type virus (BD6TB9RI, solid line) and the patient-derived PR-RT 
recombinant virus (BD6TB9RI228, dash line). The dose-response curves were obtained by plotting the inhibition percentage versus the log10 of drug concentration. The IC50 
was calculated and is illustrated by a nonlinear regression curve. The error bars indicate means ± SEM. Changes in drug susceptibility were determined by dividing the IC50 
of the test sample by the IC50 of the wild type (WT). 
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Fig. 25 Phenotypic drug susceptibility to PR and RT inhibitors representing the CRF02_AG wild type virus (BD6TB9RI, solid line) and the patient-derived PR-RT 
recombinant virus (BD6TB9RI273, dash line). The dose-response curves were obtained by plotting the inhibition percentage versus the log10 of drug concentration. The IC50 
was calculated and is illustrated by a nonlinear regression curve. The error bars indicate means ± SEM. Changes in drug susceptibility were determined by dividing the IC50 
of the test sample by the IC50 of the wild type (WT).  
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Fig. 26 Phenotypic drug susceptibility to PR and RT inhibitors representing the CRF02_AG wild type virus (BD6TB9RI, solid line) and the patient-derived PR-RT 
recombinant virus (BD6TB9RI41, dash line). The dose-response curves were obtained by plotting the inhibition percentage versus the log10 of drug concentration. The IC50 
was calculated and is illustrated by a nonlinear regression curve. The error bars indicate means ± SEM. Changes in drug susceptibility were determined by dividing the IC50 
of the test sample by the IC50 of the wild type (WT).  
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 3.3.4 Reproducibility of the phenotypic drug susceptibility assay 
 Drug susceptibility experiments were repeated three to four times to evaluate the 
reproducibility of the IC50 for each drug in a control virus (BD6TB9RI) and recombinant 
viruses (five patient-derived recombinant viruses and one chimeric BD6TB9RINL virus). 
Each assay was performed in triplicate. The mean of IC50s, standard error of mean (SEM) 
and coefficient of variation (CV) was calculated. As demonstrated in Table 11, the 
respective phenotypic resistance profiles can be reproducibly generated in these 
recombinant viruses. 
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Table 11. Reproducibility of drug susceptibility assays with CRF02_AG based plasmid backbone  
 
  PIs (nM)  NRTIs (μM)  NNRTIs (nM) 
Sample and Statistics a LPV IDV DRV RTV TPV   AZT d4T 3TC ddI FTC TDF   NVP EFV ETR 
BD6TB9RIb Mean IC50 1.78 15.30 1.07 11.37 137.97  0.07 2.54 1.16 3.75 0.45 1.44  80.42 1.00 1.18 
 SEM 0.13 2.03 0.02 0.65 27.36  0.004 0.25 0.12 0.63 0.04 0.12  1.83 0.24 0.11 
 CV 0.07 0.13 0.02 0.06 0.02  0.05 0.10 0.10 0.17 0.09 0.08  0.02 0.24 0.10 
BD6TB9RI120c Mean IC50 55.75 450.47 1.86 164.87 221.10  5.18 12.25 >500 15.08 >50 10.73  141.00 0.90 1.62 
 SEM 3.77 52.66 0.26 33.90 12.71  0.80 2.89 ND 1.78 ND 2.82  19.67 0.22 0.23 
 CV 0.07 0.12 0.14 0.21 0.06  0.15 0.24 ND 0.12 ND 0.26  0.14 0.24 0.14 
BD6TB9RI127c Mean IC50 9.06 17.32 1.14 26.36 136.70  0.67 5.44 2.16 5.61 0.75 4.14  52.55 0.28 0.23 
 SEM 1.22 2.41 0.09 0.62 23.20  0.15 0.97 0.56 0.15 0.06 0.32  13.12 0.04 0.05 
 CV 0.13 0.14 0.08 0.02 0.17  0.23 0.18 0.26 0.03 0.08 0.08  0.25 0.14 0.23 
BD6TB9RI228c Mean IC50 0.73 6.05 0.47 3.52 9.26  0.02 7.53 34.47 16.39 11.33 6.54  >10,000 384.30 15.10 
 SEM 0.09 0.61 0.06 0.32 1.04  0.005 0.94 6.67 4.24 4.13 0.32  ND 64.94 1.74 
 CV 0.12 0.10 0.14 0.09 0.11  0.21 0.13 0.19 0.26 0.36 0.05  ND 0.17 0.12 
BD6TB9RI273c Mean IC50 1.58 7.83 0.95 6.38 30.80  4.52 4.99 >150 5.53 >50 3.43  14.93 0.21 0.63 
 SEM 0.09 2.81 0.02 0.38 10.32  1.22 0.72 ND 1.53 ND 0.98  0.50 0.04 0.22 
 CV 0.06 0.36 0.02 0.06 0.33  0.27 0.14 ND 0.28 ND 0.28  0.03 0.20 0.35 
BD6TB9RI41c Mean IC50 82.19 119.03 0.95 67.81 30.74  0.14 2.95 >500 15.67 >50 2.41  2,982.67 8.86 0.22 
 SEM 7.28 3.26 0.13 1.62 21.53  0.03 0.59 ND 4.20 ND 0.44  457.40 1.74 0.02 
 CV 0.09 0.03 0.13 0.02 0.7  0.25 0.20 ND 0.27 ND 0.18  0.15 0.20 0.09 
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Table 11. Reproducibility of drug susceptibility assays with CRF02_AG based plasmid backbone (continued) 
 
  PIs (nM)  NRTIs (μM)  NNRTIs (nM) 
Sample and Statistics a LPV IDV DRV RTV TPV   AZT d4T 3TC ddI FTC TDF   NVP EFV ETR 
BD6TB9RINLd Mean IC50 4.34 16.03 1.21 35.78 248.00  0.05 2.60 1.18 3.38 0.44 2.21  193.33 1.40 1.59 
 SEM 0.66 0.54 0.03 6.31 7.98  0.007 0.60 0.37 0.12 0.04 0.42  16.69 0.16 0.19 
 CV 0.15 0.03 0.03 0.18 0.03  0.14 0.23 0.31 0.04 0.10 0.19  0.09 0.11 0.12 
NL4-3e Mean IC50 3.40 19.68 1.18 30.77 313.80  0.12 3.57 0.76 4.25 0.28 2.92  98.32 1.28 1.35 
 SEM 0.48 3.32 0.04 4.51 44.94  0.02 0.65 0.10 0.48 0.03 0.24  2.06 0.04 0.13 
 CV 0.14 0.17 0.03 0.15 0.14  0.16 0.18 0.13 0.11 0.12 0.08  0.02 0.03 0.10 
 
a = Drug susceptibility experiments were repeated at least 3 times to evaluate the IC50 for each drug from control and sample viruses. The mean IC50s, standard error of mean 
(SEM) and coefficient of variation (CV) were calculated; b = control virus (CRF02_AG); c = patient-derived recombinant viruses; d = chimeric virus [plasmid contained PR 
and RT region from pNL4-3 (subtype B) and backbone from pBD6 (CRF02_AG)]; e = subtype B virus; ND = not done. 
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4 Discussion 
 The present study provides a comprehensive analysis of drug resistance mutations 
of non-subtype B HIV-1, particularly CRF02_AG strain which is circulating in Burkina 
Faso. The importance of this study relates to the genotypic and phenotypic 
characterization of drug resistance mutation variants. The genotypic assay was performed 
by two different methods, namely; direct sequencing and clonal analysis, to determine the 
development of resistance mutations as well as the persistence and distribution of 
resistance variants in HIV-1 infected individuals. For the phenotypic assay, the plasmid 
backbone from the CRF02_AG subtype was generated. This tool would greatly facilitate 
the study of the antiretroviral drugs response of CRF02_AG variant. Overall, this study 
gives an insight into genetic characteristics of CRF02_AG strain which provides useful 
information and better understanding about development of drug resistance mutations and 
antiretroviral drug response in HIV-1 non-subtype B. 
 
 
4.1 Absence of enfuvirtide (T-20) -associated resistance 
mutations among drug naïve Burkinabes 
 Resistance mutations to T-20 are mediated by amino acid substitutions within 
HR1 at positions 36-45 including G36D/S, G36V/E, V38A/E/M, Q40H, N42T, and N43D 
(Marcelin et al., 2004; Jonhson et al., 2008). Among 38 drug naïve patients in Burkina 
Faso, no amino acid mutation was found in the highly conserved three amino acid motif 
at codons 36-38 (GIV) that are important determinants of viral susceptibility to T-20 
(Aghokeng et al., 2005). This finding confirms a previous study that natural T-20 
genotypic resistance is rare in drug naive individuals (Roman et al., 2003). The L54M and 
Q56K polymorphisms which were recently found to cause approximately 5-fold reduced 
sensitivity to inhibition by T-20 (Chinnadurai et al., 2005; Sen et al., 2009) were observed 
in 38% and 75% of all CRF02_AG samples, respectively. The N42S polymorphism 
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which was found in HR1 sequences from 36 patients in this study is subtype-specific and 
polymorphism at this position is reported to be associated with T-20 hypersusceptibility 
(Hudelson et al., 2009; Roman et al., 2003). In addition, the N126K and S138A mutations 
in HR2 which contribute to the reduction of T-20 susceptibility (Lu et al., 2006; Xu et al., 
2005) were also detected from the study samples. Other mutations, such as N140I, which 
provide immunologic gain (Sen et al., 2009) were found in some samples in this 
study.There were some polymorphisms observed in the HR1 and HR2 regions among 
patient sequences whose phenotypic implications are still unknown. It needs to be further 
determined whether these polymorphisms lead to phenotypic changes in these CRFs.  
 In summary, the lack of any known T-20 resistance mutations among the HIV 
subtypes and CRFs circulating in Burkina Faso implies that this drug has not been 
introduced in this area and it could be used in patients failing other drug regimens. 
Detailed phenotypic studies using primary isolates from this country will be useful. 
 
 
4.2 NVP associated resistance mutations are prevalent and 
persist in plasma and breast milk 
 This study demonstrates the presence and persistence of NVP-associated 
resistance mutations as well as the compartmentalization of HIV-1 population in paired 
plasma and breast milk or breast milk cells from 17 NVP-naïve and -exposed women 
from Nouna, Burkina Faso. Genetic analyses of these patients’ sequences by direct 
sequencing and clonal analysis provide an insight into the distribution pattern of HIV 
variants in these compartments.  
 In this present study, HIV infected breast feeding women in Nouna, a rural area of 
Burkina Faso, were infected mostly with CRF02_AG (64%) but also included 
CRF06_cpx (35%). This observation confirms the co-dominant distribution of 
CRF02_AG and CRF06_cpx in this area (Tebit et al., 2006). The co-dominant circulating 
between CRF02_AG and CRF06_cpx was also previously reported in Bobo-Dioulasso in 
Burkina Faso (Manigart et al., 2004) and in Niger, the neighboring country of Burkina 
Faso (Mamadou et al., 2002). In contrast to rural area, the CRF06_cpx was reported as 
the predominant strain in Ouagadougou, the capital city of Burkina Faso (Ouedraogo-
Traore et al., 2003). 
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 4.2.1 Detection of NVP-associated resistance mutations by direct 
 sequencing  and clonal analysis 
 Direct PCR sequencing or population-based sequencing can only identify variants 
that constitute more than 20% of the virus population (Palmer et al., 2005, 2006a). This 
method is therefore not sensitive enough to detect minor variants that harbor resistance 
mutations. Several studies have shown that minor drug-resistant variants that are not 
detected by direct sequencing are clinically relevant and often responsible for the 
virological failure of a new antiretroviral treatment regimen (Jourdain et al. 2004; Palmer 
et al. 2006b). By using direct sequencing, NVP resistance mutations were detected in 8% 
of infected mothers in the study, similar to the range reported from previous studies 
(Jourdain et al., 2004; Cunningham et al., 2002; Eshleman et al., 2004). This, however, 
increased to 46% by clonal analysis, in accordance with earlier studies confirming that a 
higher prevalence of resistance mutations could be detected by clonal analysis (Becquart 
et al., 2002, 2007; Kassaye et al., 2007).  
 
 4.2.2 Development and persistence of drug resistance mutations 
 among NVP-exposed women 
 Several studies have reported the development of NVP resistance mutations 
within several weeks after SD-NVP exposure in patients infected with different HIV-1 
subtypes (Eshleman et al., 2001; Jackson et al., 2000; Lee et al., 2005). In this study, the 
development of NVP resistance mutations was observed in some patients within three to 
ten days after SD-NVP exposure (Table 4). However, because the pre SD-NVP exposure 
samples were not sequenced, the possibility that some of the mutations existed due to the 
transmission of resistant variants before NVP exposure cannot be excluded. Such rapid 
development of resistance mutations was also previously detected within ten days 
postpartum from patients infected with CRF01_AE in Thailand (Jourdain et al., 2004).  
 The development of NVP resistance mutations could be due to several factors and 
has been extensively reported in prevention of HIV mother-to-child transmission 
programs in Africa (Eshleman et al., 2001; Jackson et al., 2000). Firstly, the long half-life 
of nevirapine which allows a prolonged sub-therapeutic level providing long term 
selective pressure for the emergence of resistance strains (Mirochnick et al., 1998). 
Secondly, a single mutation K103N (from AAA to AAT or AAC) or Y181C (from 
TAT/TAC to TGT/TGC) can cause a high level resistance to NVP. Finally, the 
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possibility that minor variants harboring these mutations are likely to be present in 
undetectable levels in infected women prior to NVP administration (Havlir et al., 1996). 
 In this study, the K103N mutation was more frequently selected compared to the 
Y181C mutation (Table 4). This selection may reflect the fitness advantage of K103N 
over Y181C (Richman et al., 1994; Eshleman et al., 2001). Moreover, because of the 
slight reduction of the replicative capacity of K103N, this variant is not completely 
overgrown by the wild type variant in the absence of NVP selective pressure (Hance et 
al., 2001)  and may replicate at low frequencies (Nicastri et al., 2003) or preserved 
latently in reservoirs (Briones et al., 2006). At twelve months post SD-NVP exposure, the 
K103N variant was still detectable by clonal analysis but not by direct sequencing (1 of 
15 plasma clones). This is consistent with previous studies which reported the persistence 
of K103N variants more than one year post NVP administration (Flys et al., 2005; Palmer 
et al., 2006b). Early reports on the effects of SD-NVP raised concerns that the persistence 
of NVP-related mutations could affect future treatment with NNRTIs or even a 
subsequent administration of SD-NVP in a second pregnancy. However, studies of 
Jourdain et al. (2004) and Lockman et al. (2007) suggest that given enough time between 
the initial NVP exposure and the subsequent administration, these resistance variants may 
fade out. 
 Beside the NVP resistance mutations, NRTIs resistance mutations were also 
detected in this study. The observation of two NRTI resistance mutations, K65R and 
M184I, from two NVP-exposed women confirms our previous findings that these patients 
might have been exposed to other antiretroviral drugs or misreported their therapeutic 
histories, a common phenomenon in Burkina Faso (Tebit et al., 2009). 
 
 4.2.3 Prevalence of NVP-associated resistance mutations among 
 naïve  patients 
 The prevalence of resistance mutations to all classes of antiretroviral drugs in 
HIV-1 naïve patients varies between 8-20% (Little et al., 2002; Oette et al., 2006). In a 
previous study among drug naïve patients in Burkina Faso, we found a high prevalence of 
NRTIs and NNRTIs resistance mutations of 10.6% and 6.1% respectively (Tebit et al., 
2009). Although no K103N or Y181C resistance mutations were detected among drug 
naïve patients in the present study, other NVP resistance mutations such as V106A, 
V108I as well as E44D mutation which causes low level resistance to NRTIs were also 
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detected in naïve patients (Table 4). This finding suggests that resistance variants are 
circulating and may be transmitted to drug naïve patients in this area.  
 
 4.2.4 Compartmentalization of virus populations in plasma and 
 breast milk 
 Compartmentalization occurs when a small population of variants is partially 
restricted from entering or exiting an anatomical site (Nickle et al., 2003). Moreover, 
difference of target cells, tissue specific and immune pressure in distinct anatomical sites 
may contribute to the independent selection of a variant population for further replication 
in such anatomical compartments (Becquart et al., 1999; Kemal et al., 2003; McKeating 
et al., 1989). Previous studies demonstrated contradictory results of HIV-1 
compartmentalization in plasma and breast milk (Becquart et al., 2002, 2007; Henderson 
2004). In this study, three different distribution patterns of viral populations between 
plasma and breast milk or breast milk cells were observed from 22 paired samples 
namely; compartmentalized (11 of 22 cases), partial-compartmentalized (1 of 22 cases), 
and non-compartmentalized (10 of 22 cases) (Fig. 14 and 15).  
 Compartmentalization in breast milk can be influenced by breast infections such 
as mastitis or abscesses. Inflammatory chemokine secretion in cases of mastitis or abscess 
may impair the blood-mammary gland permeability and lead to the migration of virus 
populations from plasma into the breast milk compartment or vice versa (Becquart et al., 
2007; Pillay et al., 2000). Furthermore, mastitis has been reported to increase the virus 
load of breast milk (Semba et al., 1999). Unfortunately, patient clinical data about the 
breast pathology at the sampling time were not available; therefore, it cannot be stated 
categorically, if compartmentalization was influenced by mastitis or other breast 
infections.  
 The viral load in breast milk was significantly lower than in plasma (Table 3), a 
finding which is in agreement with previous studies which have shown that some 
secretions in breast milk, such as lactoferrin or the local humoral immune response, may 
inhibit virus replication or affect the viability of free virus particles and, therefore, 
contribute to the low virus copies in breast milk (Becquart et al., 1999; Koulinska et al., 
2006; Pillay et al., 2000; Viani et al., 1999) 
 Breast milk from HIV infected women contains both cell-free virus particles and 
cell-associated virus. Transmission of HIV-1 during early stage of lactation is frequently 
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associated with cell-associated virus whereas transmission of cell-free virus frequently 
occurs at later stages of lactation mostly after nine months postpartum (Koulinska et al., 
2006). To characterize the difference of virus population within breast milk, the viral 
RNA reflecting the cell-free virus and viral DNA reflecting the cell-associated virus were 
amplified from five patients. The viral RNA in breast milk revealed a closer genetic 
relationship with virus in plasma, but clearly distinct from viral DNA in breast milk in 
four of five patients. As observed previously by Becquart and his colleagues (2002, 
2007), genetic difference between viral RNA and DNA in breast milk indicates that cell-
free virus was not produced by the majority of infected cells in breast milk. This may be 
caused by differences of cellular composition in blood and breast milk in which epithelial 
cells are the predominant cell population (Becquart et al., 2007). These cells are not 
highly permissive to HIV infection and produce low copies of virus in vitro (Toniolo et 
al., 1995). Furthermore, most of infected cells in milk are found to be latently infected 
with transiently silent viruses (Boulerice et al., 1990). Thus, it is possible that free virus in 
breast milk originated from two major cell populations, macrophages and lymphocytes 
which could be infected locally at sub-mucosal sites within the mammary gland (Becquart 
et al., 2002, 2007) or migrated from other peripheral mucosal sites (Kourtis et al., 2003). 
Moreover, a study by Lee et al. (2005) showed that viruses from the left and right breasts 
differed in the resistance mutations which they carried suggesting independent evolution 
and compartmentalization. This difference in drug resistance mutations might be 
influenced by several factors such as cytokine secretion or pharmacokinetics of a 
particular drug in individual compartment (Kepler and Perelson, 1998). 
 In conclusion, compartmentalization of virus populations occurs but is not a 
dominant phenomenon between plasma and breast milk.  
 
 4.2.5 HIV diversity and divergence during viral evolution in 
 plasma and breast milk  
 Previous studies have reported a lower viral diversity of genital tract variants 
compared to those from blood plasma (De Pasquale et al., 2003; Ellerbrock et al., 2001). 
In this study, diversity of the HIV-1 population was significantly less in breast milk and 
breast milk cells than in plasma (Fig. 17; Table 5). Taken together, these findings indicate 
the restriction of the pool of HIV-1 quasispecies undergoing active replication within the 
mammary compartment. In contrast, HIV-1 quasispecies circulating in plasma originate 
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from virus replication occurring at numerous sites of lymphoid tissues throughout the 
body (Cohen et al., 1995; Erice et al., 2001). 
 The viral divergence in plasma originating from six patients at multiple time 
points post NVP exposure were mostly similar, and showed no significant difference 
(Table 6). In contrast, there was a significantly divergent virus population in breast milk 
(1 case, Table 6) and breast milk cells (1 case, Table 6). Such differences could be due to 
local factors such as cell composition (Becquart et al., 2007), anti-viral substances (Swart 
et al., 1996) or local specific immunity (Becquart et al., 1999) as well as 
pharmacokinetics of antiretroviral drug concentration in mammary gland which may 
differ markedly from the systematic compartment (Bennetto-Hood et al., 2007). 
Alternatively, this could be due to changes in the cellular and immune environment 
overtime in maternal milk (Koulinska et al., 2006). Thus, these different factors in 
individual compartments could have acted as a driving force influencing the viral 
divergence within such compartments. 
 
 
4.3 Phenotypic characterization of resistance mutations in 
CRF02_AG plasmid backbone 
 Treatment with highly active antiretroviral therapy (HAART) has significantly 
reduced the rate of mortality and disease progression of HIV-1 infected patients. 
Selection for HIV-1 variants with decreasing drug susceptibility caused by mutations in 
the viral protease and reverse transcriptase represents the major reason of treatment 
failure (Perrin and Telenti, 1998). Therefore, resistance testing is recommended to guide 
the choice of more efficacious drug regimens after the first or multiple treatment failure 
(Hirsch et al., 2003) or at the initiation of therapy in drug naïve patients at risk of 
infection with resistant virus (Little et al., 2002). Current methods for the detection of 
drug resistance include genotypic and phenotypic assays. Although both methods are of 
clinical utility, genotypic and phenotypic assays have multiple advantages and 
disadvantages. Genotypic assays are relatively rapid but difficult to interpret when 
complex mutational patterns, cross-resistance, or resistance reversal are identified 
(Gingeras et al., 1996, Hertogs et al., 1998). On the other hand, phenotypic test measure 
directly the ability of HIV to grow in the presence of each antiviral drug. Thus, 
phenotypic testing can provide direct evidence of resistance including information on 
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cross-resistance, multidrug resistance, or resistance reversal (Paolucci et al., 2003; Ross et 
al., 2001). However, phenotypic assay which used the viruses derived directly from the 
patient by cocultivation methods were both difficult to perform and time consuming 
(Japour et al., 1993). The development of the recombinant virus assay (Kellam and 
Larder, 1994) demonstrated the way for rapid, reproducible, and large scale phenotypic 
analysis of drug resistance. Recombinant viruses are generated by amplification of patient 
derived protease-reverse transcriptase (PR-RT) sequences which are then cloned or 
introduced into a PR-RT-deleted provirus backbone either by homologous recombination 
(Hertogs et al., 1998) or direct cloning (Garcia-Perez et al., 2007; Petropoulos et al., 
2000).  
 
 4.3.1 Effect of CRF02_AG plasmid backbone on susceptibility to 
 antiretroviral drugs 
 Previously, the provirus backbone used for recombinant viral system was 
constructed based on HIV-1 subtype B (Garcia-Perez et al., 2007; Hertogs et al., 1998; 
Petropoulos et al., 2000) which dominates in developed countries, although this subtype 
represents only a small fraction of global HIV-1 infection (Osomanov et al., 2002). The 
current epidemic of HIV-1 infection in African countries is dominated by non-B subtype 
(Janssens et al., 2000; Spira et al., 2003). This study outlines the phenotypic aspects of a 
recombinant viral assay developed by generating a CRF02_AG proviral plasmid 
backbone (pBD6TB9RI) based on the CRF02_AG subtype which has been previously 
reported as one of the dominant circulating HIV-1 strains in Burkina Faso (Tebit et al., 
2006). CRF02_AG had also been previously reported to have a higher replicative fitness 
compared to parental subtypes A and G (Njai et al., 2006; Konings et al., 2006). 
Phenotypic assays using a backbone with similar genetic background may reveal useful 
information about antiviral drug susceptibility in non-subtype B strains. To investigate the 
effect of proviral backbone on antiviral drug response, a chimeric virus carrying the PR-
RT fragment from subtype B, pNL4-3 was generated. The result showed that similar drug 
susceptibility profiles to RTIs (Fig. 21; Table 7) between control CRF02_AG virus 
derived from proviral backbone (pBD6TB9RI), chimeric CRF02_AG/subtype B virus 
(BD6TB9RINL), and subtype B (NL4-3) virus was observed as reported by Fleury et al. 
(2006). However, minor differences in drug susceptibility between control CRF02_AG 
virus, chimera, and subtype B virus were observed for some PIs (Fig. 21; Table 7), i.e. the 
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control CRF02_AG virus was shown to be more susceptible to RTV and TPV than 
subtype B virus (NL4-3) without statistical significance (Fig. 21; Table 7). This 
observation is in agreement with a previous study which reported a higher susceptibility 
to RTV and TPV in drug naïve patients infected with CRF02_AG than subtype B 
(Abecasis et al., 2006). 
 
 4.3.2 Phenotypic drug susceptibility testing with patient-derived  
 recombinant viruses 
 In the present study, patient-derived sequences were re-amplified from frozen 
PCR products previously used for genotypic testing and were then incorporated into the 
pol-deleted CRF02_AG proviral backbone by direct cloning (Petropoulos et al., 2000). 
This method is highly efficient and reproducible compared to the relatively inefficient and 
random process of homologous recombination. Therefore, the recombinant viral system 
described here could provide both genotypic and phenotypic information from the same 
patient sample. Moreover, the comparison of the amino acid substitutions between 
original plasma samples previously used for genotypic assays and corresponding 
recombinant viruses demonstrated a nearly identical substitution patterns (Table 9). This 
observation suggests that in vitro phenotypic resistance pattern could reflect the resistance 
pattern of circulating viruses tested by genotypic assay (Hertogs et al., 1998).  
 Several studies have demonstrated the comparable in vitro susceptibility of non-B 
subtype viruses to most antiretroviral drugs (Shafer et al., 1999; Toni et al., 2002; Weidle 
et al., 2001). A good correlation was observed between resistance mutations patterns and 
the drug susceptibility profiles in cases of RT inhibitors in this study as well (Table 8 and 
10). In addition, most of the patient-derived recombinant viruses exhibited concordant PI 
susceptibility profiles and genotype (Table 8 and 10). However, some discordance 
between drug susceptibility and resistance mutations to some PIs was found in two 
patient-derived recombinant viruses (BD6TB9RI 120 and BD6TB9RI 41). These two 
recombinant viruses which harbor major resistance mutations to PIs were susceptible to 
DRV and TPV (Fig. 22 and 26; Table 8 and 10). Moreover, other two recombinant 
viruses (BD6TB9RI 228 and BD6TB9RI 273) with no major mutations to PIs were found 
to be hypersusceptible to TPV (Fig. 24 and 25; Table 8 and 10). Previous studies have 
shown that the resistance mutations to PI may differ between subtypes (Cane et al., 2001; 
Caride et al., 2001). Furthermore, some polymorphisms occurring at positions which are 
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not associated with subtype B resistance or do not present in subtype B, may alter the PI 
susceptibility in non-B subtypes (Abecasis et al., 2006; Fleury et al., 2006; Kantor and 
Katzenstein, 2003). Therefore the resistance mutations which are associated with PI 
resistance in subtype B as well as polymorphisms found in subtype B may not be 
applicable for some non-B subtypes. 
  
 4.3.3 Reproducibility of phenotypic drug susceptibility testing 
 In order to obtain better sensitivity and reproducibility of this phenotypic assay, 
the recombinant virus stocks generated from transfection were used to infect TZM target 
cells in presence or absence of antiviral drugs and viral replication was measured through 
luciferase activity 48 hours after infection. This strategy is more sensitive than HIV-gag 
p24 detection and less time is required to perform the recombinant viral assay compared 
to standard virus isolation from peripheral blood mononuclear cells which typically takes 
from 1 to 4 weeks (Tebit et al. 2002). This method also avoids selection of minority virus 
population (Garcia-Perez et al., 2007; Kusumi et al., 1992). Furthermore, the high level of 
reproducibility obtained from the present study (Table 11) suggests that this assay is able 
to distinguish minor differences in susceptibility to antiretroviral drugs. 
  
 
4.4 Future perspectives 
 Although clonal analysis provides a  sensitive means of detecting NVP-resistance 
variants, other more sensitive methods such as the oligonucleotide ligation assay-OLA 
(Troyer et al., 2008) and pyrosequencing have been applied (Le et al., 2009). All the 
paired breast milk and plasma samples used for this study are presently being analyzed by 
OLA and pyrosequencing to compare these viral quasispecies to those observed by 
normal sequencing. The point of interest will be the detection of low level K103N and 
Y181C mutations in plasma, breast milk and breast milk cells. Also, pyrosequencing is 
being used to analyze the C2-V3 of the envelope gene from these samples. These 
analyses will provide a clearer picture of the quasispecies population present in these 
compartments. Screening of minority populations in envelope is important for co-receptor 
based treatment regimens (CCR5 antagonists) which will definitely be introduced in 
Africa with time. 
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 The influx of antiretroviral therapy in Africa within the last few years has been 
substantial. This increase has been met with a rise in prevalence of drug resistance 
mutations among drug naïve HIV infected individuals. Unfortunately, the rise in 
treatment has not been equally met by an increase in infrastructure for resistance 
diagnosis. The future however, does not look completely bleak with the noticeable rise in 
the number of Sequencers in African countries following scale up in ART. Although 
genotypic analysis through sequencing will be easier to perform in this set up, the 
development of phenotypic methods as well as cheaper methods to monitor resistance in 
Africa is needed.  Phenotypic assays most often referred to as recombinant viral assays 
have been made based mostly on subtype B. By modifying a previously described 
CRF02_AG infectious molecular clone, we have been able to generate a CRF02_AG 
based vector which was used to create chimeric viruses by introducing PR and RT 
amplified directly from patient RNA. This method will be improved in the near future by 
modifying the CRF02_AG clone to suit the yeast recombination cloning method which is 
actually more efficient and represents the quasispecies present in a patient’s sample. We 
hope to extend this cloning strategy to include the envelope gene in order to facilitate 
detection of viral phenotype (CCR5 or CXCR4 using isolates) in patients who would be 
treated with receptor based regimens such as Enfuvirtide (T-20) or Maraviroc. Adapting 
the yeast cloning strategy will enable us to test several drug naïve sequences from both 
CRF02_AG and CRF06_cpx strains for their susceptibility against PR and RT inhibitors. 
Such studies will help explain the preliminary reports from our previous study which 
suggested that CRF06_cpx strains develop NRTIs drug resistance mutations especially 
TAMs faster than CRF02_AG strains. In brief, the CRF02_AG based recombinant assay 
will be useful in screening different new drugs and also testing for viral fitness. 
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Appendix 1  List of abbreviations 
 
3TC Lamivudine 
AZT Zidovudine 
AIDS Acquired Immunodeficiency Syndrome 
AMP ampicillin 
bp base pair 
BM breast milk 
BMc breast milk cells 
d4T Stavudine 
ddI Dideoxyinosine 
DMEM Dulbecco's modified eagle medium 
DMSO dimethylsulfoxide 
DNA desoxyribonucleic acid 
dNTPs deoxy-nucleoside-triphosphates 
ddNTPs dideoxy-nucleoside-triphosphate 
DRV Darunavir 
E. coli Escherichia coli 
EDTA ethylene-diamine-tetra-acetic acid 
ELISA enzyme-linked immunosorbent assay 
EFV Efavirenz 
env gene coding viral envelope glycoprotein 
ETR Etravirine 
FCS fetal calf serum 
FTC Emtricitabine 
Fig. figure 
gp41 glycoprotein 41 
h hour 
HAART highly active anti-retroviral therapy 
HEPES 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
HIV Human Immunodeficiency Virus  
HR1 heptad repeat 1 
HR2 heptad repeat 2 
IC50 inhibition constant; the concentration of substance that provides 
50% inhibition to certain reaction 
IDV Indinavir 
kb kilo-base pair 
LB Luria-Bertani broth 
LPV Lopinavir 
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M molar concentration 
min minute 
NRTIs nucleoside reverse transcriptase inhibitors 
NNRTIs non-nucleoside reverse transcriptase inhibitors 
NVP Nevirapine 
nt  nucleotide 
OD optical density 
p24 alternative designation of the HIV-1 CA protein 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PIs protease inhibitors 
PL plasma 
PMTCT prevention mother-to-child transmission 
pol gene coding viral enzymes 
PR protease 
RNA ribonucleic acid 
rpm rotations per minute 
RPMI Roswell Park Memorial Institute 1640 Medium 
RT reverse transcriptase 
RTIs reverse transcriptase inhibitors 
RTV Ritonavir 
SD-NVP single dose Nevirapine 
TAE Tris-acetate-EDTA buffer 
TBS Tris buffered saline 
TDF Tenofovir 
Tm melting temperature 
TPV Tipranavir 
Tris Tris(hydroxymethyl)aminomethane 
u unit 
UV ultraviolet light 
wt wild-type 
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Appendix 2  List of plasmids 
 
name Prepared by restriction vector resistance 
pBD6-15 (Tebit et al., 2003) D. M. Tebit  pCR-XL-TOPO Kana 
     
pBD6TB9 (unpublished) D. M. Tebit ApaI/StuI pGEM-T-easy AMP 
     
pBD6TB9RIa K. Sathiandee EcoRI/StuI pGEM-T-easy AMP 
     
pBD6TB9RINLa K. Sathiandee EcoRI/StuI pGEM-T-easy AMP 
     
pLucBD6TB9 (unpublished) D. M. Tebit EcoRI/StuI pGEM-T-easy AMP 
     
pLucBD6TB9RI (unpublished) K. Sathiandee EcoRI/StuI pGEM-T-easy AMP 
     
pBD6TB9A (unpublished) K. Sathiandee ApaI/StuI pGEM-T-easy AMP 
     
All plasmids which contained 
patients-derived RT fragment 
(to determine NVP resistance 
mutation)a 
K. Sathiandee EcoRI pCR2.1-TOPO Kana 
 
a = manuscript in preparation. 
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Appendix 3  List of oligonucleotides 
 
List of oligonucleotides used for amplification of different parts of HIV-1. The oligonucleotides are listed 
according to their number in the list of the department of Virology. The sequences are always oriented from 
5’- to 3’-end. The presence of restriction sites is underlined. 
 
# name sequence location used for  
a Mlubase1 GGGCCCACGCGTGATGGGTTAATTTACTCCAAGA
AAAGACAAGA 
4-40 of HXB2 introduction of 
new EcoRI site 
     
a Env5+ TCAGACCTGGAGGAGGAGATATGA 7627-7650 of HXB2 amplify gp41 
domain 
     
1013 GP40F1 TCTTAGGAGCAGCAGGAAGCACTATGGG 7789-7816 of HXB2 amplify gp41 
domain 
     
1014 GP41R1 AACGACAAAGGTGAGTATCCCTGCCTAA 8347-8375 of HXB2 amplify gp41 
domain 
     
1016 GP47R2 TTAAACCTATCAAGCCTCCTACTATCATTA 8265-8294 of HXB2 amplify gp41 
domain 
     
1669 RT-rev-
StuI 
TTTCTGCTACTAGGCCTTTTGCTGGGTCATAATAG
ACTCCATGTACAGGTTCTTTT 
3550-3555 of pBD6 introduce new 
EcoRI site 
or amplify RT 
region 
1725 RT1-for AGTAGGACCTACACCTGTCAACATAATTGG 2491-2520 of pBD6 amplify RT 
region 
     
1726 RT3-for AATATGTTGACTCAGATTGGTTGTACTTTAAAT  T 2525-2558 of pBD6 amplify RT 
region 
     
1727 RT4-rev CTTTTAGAATTTCCCTGTTCTCTGCCAATTC 3474-3504 of pBD6 amplify RT 
region 
     
2118 Pro-for-
EcoRI 
GAGGGACAAGGAATTCTACCCTCCTTTAGCTTCCC
TCAAA 
2231-2270 of pBD6 introduce new 
EcoRI restriction 
site 
     
2119 Pro-rev-
EcoRI 
GCTAAAGGAGGGTAGAATTCCTTGTCCCTCGGTTC
CTGCT 
2221-2260 of pBD6 introduce new 
EcoRI site 
     
2190 KnockRI-F 
 
ATGTCACACAAGAATTTGGGATTCCCTACAATCCC
CAAAGTC 
4641-4682 of pBD6 knock out EcoRI 
site 
     
2191 KnockRI-R TGGGGATTGTAGGGAATCCCAAATTCTTGTGTGAC
ATTTG 
4638-4677 of pBD6 knock out EcoRI 
site 
     
2261 7Stu-R-
BD6 
CTGTATTTCTGCTATTAGGCCTTTTGATGGGTCAT
AATAC 
3500-3539 of 
pNL4-3 
amplify PR/RT 
region from 
pNL4-3 
     
2287 7EcoRI-F-
BD6 
GAGCCGATAGACAAGGAATTCTATCCTTTAGCTTC 2218-2252 of 
pNL4-3 
amplify PR/RT 
region from 
pNL4-3 
a = Tebit 2001 
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Appendix 4 PCR reaction components 
 
 The RT-PCR reaction contained: 
25 µl 2x Reaction mix (a buffer contain 0.4 mM of 
each dNTP, 3.2 mM MgSO4) 
2 µl SuperScript™ III RT/Platinum® Taq mix 
1 µl each forward/reverse -Primer (10 µM) 
0.01 pg - 1 ng RNA template 
Sterile distilled water to 50 µl total volume 
 
 
 The PRC reaction for fragment less than 1 kb contained: 
  
5 µl 10x PCR buffer (1.5 mM MgCl2) 
1 µl dNTP (200 µM) 
1 µl Taq polymerase  
1 µl each forward/reverse -primer (10 µM) 
20-200 ng DNA template 
Sterile distilled water to 50 µl total volume 
 
 
 The PRC reaction for fragment greater than 1 kb contained: 
  
10 µl 5x Expand High FidelityPlus buffer (1.5 
mM MgCl2) 
1 µl dNTP (200 µM) 
0.5 µl Expand High FidelityPlus Enzyme (2.5 
U/reaction) 
1 µl each forward/reverse -primer (10 µM) 
2 - 500 ng 
100 pg - 10 ng 
genomic DNA 
plasmid DNA 
Sterile distilled water to 50 µl total volume 
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Appendix 5 Thermal cycling 
 
 The following temperature cycling protocol was used for RT-PCR: 
step temperature duration 
1: cDNA synthesis 45-60°C 15-30 min 
2: initial denaturation 94°C 2 min 
3: denaturation 94°C 15 sec 
4: annealing 55 – 65°C* 30 sec 
5: elongation 68°C 1 min/kb** 
repeat steps (3-5) 39 cycles 
6: final elongation 68°C 5 min 
 
 The following temperature cycling protocol was used for short fragment PCR: 
step temperature duration 
1: initial denaturation 94°C 2 min 
2: denaturation 94°C 10-30 sec 
3: annealing 55 – 68°C* 30 sec 
4: elongation 72°C 1 min/kb** 
repeat steps (2-4) 25-35 cycles 
5: final elongation 72°C 7 min 
 
 The following temperature cycling protocol was used for long fragment PCR: 
step temperature duration 
1: initial denaturation 94°C 2 min 
2: denaturation 94°C 10-30 sec 
3: annealing 55 – 68°C* 30 sec 
4: elongation 68-72°C 1 min/kb** 
repeat steps (2-4) 10 cycles 
5: denaturation 94°C 10-30 sec 
6: annealing 55 – 68°C* 30 sec 
7: elongation 68-72°C 1 min/kb** + 10 sec. cycle elongation for 
each successive cycle 
repeat steps (5-7) 15-25 cycles 
8: final elongation 72°C 7 min 
 
* depending on the melting temperature of the primers 
** depending on the product length (~1 kb/min) 
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Appendix 6 List of antiretroviral drug concentrations 
 
 
Antiviral 
drugs 
Serial concentration (final 
concentration) 
% DMSO (final 
concentration)d 
PIs: 
LPVa 
IDVc 
RTVa 
DRVa 
TPVa 
 
0.5, 5, 50, 500 and 1000 nM 
0.5, 5, 50, 500 and 1000 nM 
0.5, 5, 50, 500 and 1000 nM 
0.5, 5, 50, 500 and 1000 nM 
0.5, 5, 50, 500 and 1000 nM 
 
0.1% in every dilution 
0.1% in every dilution d 
0.1% in every dilution  
0.1% in every dilution  
0.1% in every dilution  
NRTIs: 
AZTb 
d4Tc 
3TCa 
ddIa 
FTCc 
TDFc 
 
0.005, 0.05, 0.5, 5 and 50 uM 
0.005, 0.05, 0.5, 5 and 50 uM 
0.05, 0.5, 5, 50 and 500 uM 
0.05, 0.5, 5, 50 and 500 uM 
0.005, 0.05, 0.5, 5 and 50 uM 
0.005, 0.05, 0.5, 5 and 50 uM 
 
0.1% in every dilution d 
0.5% in every dilution d 
0.5% in every dilution  
0.5% in every dilution d 
0.5% in every dilution d 
0.5% in every dilution d 
NNRTIs: 
NVPa 
EFVa 
ETRa 
 
0.1, 1, 10, 100, 1000 and 10000 nM 
0.1, 1, 10, 100 and 1000 nM 
0.1, 1, 10, 100 and 1000 nM 
 
0.1% in every dilution  
0.1% in every dilution  
0.1% in every dilution  
 
 a = stock solution in DMSO; b = stock solution in Tris buffer; c = stock solution in water 
 d = DMSO was added into drugs which dissolved in Tris and water. 
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